The 2-His-1-carboxylate facial triad an emerging structural motif in mononuclear non-heme iron(II)

合集下载

Amino Acid N-Carboxyanhydrides The Solid-Phase Synthesis of two Decapeptides

Amino Acid N-Carboxyanhydrides The Solid-Phase Synthesis of two Decapeptides

Ο
^,
1 1
0 CN - ο CN
*
ex s υ"
•σ
00 0
- 148° Li
ii n
- 28° (c = chlorofon
- 29° (c = acetic acic
" o"
T P"
(N
°0 1
«0 rt •H £
IO
1
o
0 0
0
06
r-
f0 es
10 CN
ε «0
CN τί-
"
10
CN
oo 1—1
1001
Leu Qrnll) Val
Sly
D-Phe Leu
Orn(Z)
Val Gly
D-fhe
•i- i.
/%e 4/a

n 'Λ.
/Pro
Ληο to/ /te
flte
/Ve
Pro
Phe
0°0
°°0
,. ^ '·*. u i. i- '-"* ··
70 ?0 J0 40 Titration no.—^ 50
Β
ο'

O
III!
l
Brought to you by | Purdue Univers Authenticated Download Date | 6/19/15 7:4
Bd. 357(1976)
-/V-2-Nitrophenylthio Amino Acid ./V-Carboxyanhydrides
„00 „00 «0 Tj- «0 rf 10 „ >0 .

HOBT EDCI

HOBT EDCI

Design,Synthesis,and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors Nobuaki Suzuki,†Takayoshi Suzuki,*,†Yosuke Ota,†Tatsuya Nakano,‡Masaaki Kurihara,§Haruhiro Okuda,§Takao Yamori,# Hiroki Tsumoto,†Hidehiko Nakagawa,†and Naoki Miyata*,†,§Graduate School of Pharmaceutical Sciences,Nagoya City Uni V ersity,3-1Tanabe-dori,Mizuho-ku,Nagoya,Aichi467-8603,Japan,Di V ision of Medicinal Safety Science,National Institute of Health Sciences,1-18-1Kamiyoga,Setagaya-ku,Tokyo158-8501,Japan,Di V ision of Organic Chemistry,National Institute of Health Sciences,1-18-1Kamiyoga,Setagaya-ku,Tokyo158-8501,Japan,and Di V ision of Molecular Pharmacology,Cancer Chemotherapy Center,Japanese Foundation for Cancer Research,3-10-6Ariake,Koto-ku,Tokyo135-8550,Japan Recei V ed February2,2009Guided by the proposed catalytic mechanism of histone deacetylases(HDACs),we designed and synthesizeda series of boronic acid-based HDAC inhibitors bearing an R-amino acid moiety.In this series,compounds(S)-18,20,and21showed potent HDAC-inhibitory activity,highlighting the significance of the(S)-aminoacid moiety.In cancer cell growth inhibition assays,compounds(S)-18,20,and21exerted strong activity,and the values of the ratio of the concentration causing50%growth inhibition(GI50)to the concentrationcausing50%enzyme inhibition(IC50),i.e.,GI50/IC50,were low.The potency of these compounds was similarto that of clinically used suberoylanilide hydroxamic acid(SAHA)(2).The results of Western blot analysisindicated that the cancer cell growth-inhibitory activity of compounds(S)-18,20,and21is the result ofHDAC inhibition.A molecular modeling study suggested that the hydrated boronic acid interacts with zincion,Tyr residue,and His residue in the active site of HDACs.Ourfindings indicate that these boronic acidderivatives represent an entry into a new class of HDAC inhibitors.IntroductionThe acetylation status of lysine residues in nucleosomal histones is tightly controlled by two counteracting enzyme families,the histone acetyl transferases and the histone deacety-lases(HDACs a).1The latter family can be divided into two categories:Zn2+-dependent enzymes and NAD+-dependent enzymes.2The Zn2+-dependent HDACs are closely connected with control of gene expression and cell cycle progression.3The inhibition of HDACs causes histone hyperacetylation and leads to transcriptional activation of genes such as p21WAF/CIP1,Gadd 45,FAS,and caspase-3,which are associated with growth arrest and apoptosis in tumor cells.4Indeed,HDAC inhibitors,such as trichostatin A(TSA,1),5suberoylanilide hydroxamic acid (SAHA,also known as vorinostat,2),6PXD-101(3),7and MS-275(4)8(Chart1),have been reported to inhibit cell growth, induce terminal differentiation in tumor cells,and prevent the formation of malignant tumors,and they have been developed as antitumor agents.Among them,SAHA has recently been approved by the FDA for treatment of cutaneous T-cell lymphoma.In addition,there are several lines of evidence indicating that HDAC inhibitors are effective as therapeutic agents for other diseases,including inflammation and neuro-degenerative diseases.9Moreover,it has recently been reported that HDAC inhibitors,such as TSA(1),SAHA(2),and valproic acid,improve the efficiency of induction of pluripotent stem cells without introduction of the oncogene c-Myc,suggesting the importance of HDAC inhibitors in regenerative medicine.10Consequently,there are many ongoing research programs to find more potent and selective HDAC inhibitors.11To date,X-ray crystal structures of human HDAC4,12 HDAC7,13HDAC8,14and archaebacterial HDAC-like protein (HDLP)15have been published.A number of potent and selective inhibitors have been identified by structure-based drug design using these crystal structures.11Recently,the catalytic mechanism of the deacetylation of acetylated lysine substrates by HDACs was proposed,based on a density functional theory QM/MM study of HDLP,16and this also offers many clues for the design of HDAC inhibitors.Herein we report the synthesis and biological activity of boronic acid-based HDAC inhibitors, which were designed on the basis of the proposed catalytic mechanism of HDACs.ChemistryCompounds5-26prepared for this study are shown in Tables 1-3.The routes used for the synthesis of the compounds are shown in Schemes1-5.Scheme1shows the preparation of R-amino acid derivatives5-10.These compounds were syn-thesized from diethyl pound27was treated with(Boc)2O to yield N-Boc pound 28was allowed to react with5-bromopent-1-ene in the presence of NaOEt in refluxing EtOH to give C-alkylated compound29. Hydrolysis of the ethyl ester of29with an equivalent amount of LiOH gave monocarboxylic acid30,and subsequent decar-boxylation reaction afforded R-amino acid derivative31. Compound31was hydrolyzed with LiOH followed by treatment with an appropriate aromatic amine in the presence of EDCI and HOBt to give amides33-38.The hydroboration reaction of amides33-38with pinacolborane using[Ir(cod)Cl]2catalyst and dppm or dppe ligand gave terminal boronic esters39-44.17 Hydrolysis of the boronic esters39-44using NH4OAc and NaIO4in acetone-water yielded boronic acids5-10.18 Scheme2shows the preparation of boronic acids11-16,in which the R-amino moiety of compounds5-10was removed.*To whom correspondence should be addressed.For T.S.:phone andfax,+81-52-836-3407;e-mail,suzuki@phar.nagoya-cu.ac.jp.For N.M.:phone and fax,+81-52-836-3407;miyata-n@phar.nagoya-cu.ac.jp.†Nagoya City University.‡Division of Medicinal Safety Science,National Institute of HealthSciences.§Division of Organic Chemistry,National Institute of Health Sciences.#Japanese Foundation for Cancer Research.a Abbreviations:HDAC,histone deacetylase;TSA,trichostatin A;SAHA,suberoylanilide hydroxamic acid;HDLP,HDAC-like protein.J.Med.Chem.2009,52,2909–2922290910.1021/jm900125m CCC:$40.75 2009American Chemical SocietyPublished on Web04/14/2009These compounds were synthesized from hept-6-enoic acid 45using the same synthetic approach as described for compounds 5-10.Scheme 3shows the preparation of R -amino acid derivatives 17-24,in which the Boc group of 6was replaced with various carbonyl moieties.These compounds were prepared from 40in three steps:deprotection of the Boc group,condensation with an appropriate aromatic carboxylic acid,and hydrolysis of the boronic esters.Scheme 4shows the preparation of malonic acid derivatives 25and 26,in which the R -aminocarbonyl moiety of compounds 18and 20was replaced with the corresponding carboxamide.These compounds were synthesized from tert -butyl ethyl malonate 66.Treatment of 66with 5-bromopent-1-ene in the presence NaH in THF yielded compound 67.The ethyl ester of 67was hydrolyzed with an equivalent amount of LiOH,followed by condensation with biphenyl-3-ylamine to give amide 69.Hydroboration,deprotection of tert -butyl ester using TFA,condensation with an appropriate aromatic amine,and hydrolysis of the boronic ester gave the malonic acid derivatives 25and 26.Scheme 5shows the preparation of optically active R -amino acid derivatives (S )-and (R )-18,20,21.These compounds were synthesized using the procedure reported by Nishino and co-workers.19Compound (RS )-31was subjected to the action of subtilisin from Bacillus licheniformis in a mixture of DMF and water to yield (S )-32as a white solid.The recovered (R )-31was hydrolyzed with LiOH to afford (R )-32.The synthesis of (S )-and (R )-18,20,21was accomplished from (S )-32or (R )-32using the procedure described for the synthesis of R -amino acid derivatives (shown in Schemes 1and 3).The enantiomeric excess of (S )-and (R )-18,20,21was determined to be >95%by chiral column chromatography.Results and DiscussionDrug Design.In 1999,Finnin et al.reported X-ray crystal structures of HDLP complexed with inhibitors.15The enzyme contains a zinc ion at the bottom of the active site,and the active center consists of a tyrosine,two aspartic acids,and three histidines.In 2006,Corminboeuf et al.carried out density functional theory QM/MM studies on the deacetylation reaction catalyzed by HDLP.16The proposed mechanism suggested by the calculation results is depicted in Figure 1a.In this mecha-nism,the carbonyl oxygen of the substrate binds the zinc ion and is located adjacent to a water molecule.The electrophilicity of the carbonyl carbon is increased by coordination to the zinc ion,and so the carbonyl carbon is attacked by the water molecule activated by His 140and His 141(HDAC1number-ing).This nucleophilic attack results in a tetrahedral transition state,which is stabilized by a zinc -oxygen interaction and by hydrogen bonds with Tyr 303and His 140.In the final step,proton transfer from His 141to the nitrogen of the intermediate triggers scission of the carbon -nitrogen bond to afford the acetate and lysine products.In designing selective HDAC inhibitors,we focused on the proposed deacetylation mechanism.On the basis of this mech-anism,we designed R -amino acid derivatives A (Figure 1b)in which the acetamide of the acetylated lysine substrate is replaced by boronic acid.Because the boron atom of the boronic acids A has a vacant p-orbital,it could be attacked by a water molecule in the active site.The generated boronic acid -H 2O “ate”complex could act as a transition state analogue of the deacetylation of acetylated lysine substrates.That is,the hydrated boronic acid would bind the zinc ion and form two hydrogen bonds with Tyr 303and His 140,which would lead to HDAC inhibition.Enzyme Assays.In our exploratory study on boronic acid-based HDAC inhibitors,we initially focused on the R 1group (Table 1and Supporting Information Figure S1).We chose various aromatic rings as the R 1group because we had already discovered that thiolate compounds bearing aromatic groups such as phenyl,3-biphenyl,and 3-quinolinyl potently inhibited HDACs both in enzyme assays and in cellular assays.11BoronicChart 1.Examples of HDACInhibitorsScheme 1aaReagents and conditions:(a)(Boc)2O,Et 3N,THF,room temp,81%;(b)NaOEt,5-bromopent-1-ene,EtOH,reflux,89%;(c)LiOH ·H 2O,EtOH,H 2O,0°C,94%for 32,99%for 30;(d)toluene,reflux,94%;(e)R 1-NH 2,1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI),1-hydroxybenzo-triazole hydrate (HOBt ·H 2O),DMF,room temp,67-95%;(f)[Ir(cod)Cl]2,bis(diphenylphosphino)methane (dppm)or 1,2-bis(diphenylphosphino)ethane (dppe),pinacolborane,CH 2Cl 2,room temp,32-93%;(g)NH 4OAc,NaIO 4,acetone,H 2O,room temp,10-92%.2910Journal of Medicinal Chemistry,2009,Vol.52,No.9Suzuki et al.acids 5-10,in which R 1is various aromatic groups and R 2is -NHBoc,were initially tested with an in vitro assay using HeLa nuclear extract with high HDAC activity (Table 1and Figure S1).Compounds 5-10showed HDAC-inhibitory activity at a concentration of 100µM,while the 3-biphenyl 6,3-quinolinyl 7,and benzthiazole 8compounds were more potent (78-86%inhibition at 100µM).Compounds 6,7,and 8inhibited HDAC activity dose-dependently with IC 50values of 12,16,and 23µM,respectively;these values are much lower than those of the other aromatic analogues 5,9,and 10.We also tested compounds 11-16,which lack the NH-Boc group of com-pounds 5-10,and they were found to be much less potent inhibitors than compounds 5-10(Table 1and Figure S1),suggesting the significance of the R -amino acid moiety.To find more potent HDAC inhibitors,we next focused on the tert -butoxy group of compound 6,the most potent inhibitorScheme 2aaReagents and conditions:(a)R 2-NH 2,EDCI,HOBt,DMF,room temp,72-95%;(b)[Ir(cod)Cl]2,dppm or dppe,pinacolborane,CH 2Cl 2,room temp,13-74%;(c)NH 4OAc,NaIO 4,acetone,H 2O,room temp,35-94%.Scheme 3aaReagents and conditions:(a)HCl,AcOEt,CHCl 3,room temp,100%;(b)R 3-COOH,EDCI,HOBt,DMF,room temp,11-100%;(c)R 3-COCl,Et 3N,CH 2Cl 2,N,N -dimethyl-4-aminopyridine (DMAP),room temp,41%;(d)NH 4OAc,NaIO 4,acetone,H 2O,room temp,19-82%.Scheme 4aaReagents and conditions:(a)NaH,5-bromopent-1-ene,THF,reflux,52%;(b)LiOH ·H 2O,tert -BuOH,H 2O,0°C,100%;(c)biphenyl-3-ylamine,EDCI,HOBt,DMF,room temp,76%;(d)[Ir(cod)Cl]2,dppm,pinacolborane,CH 2Cl 2,room temp,70%;(e)TFA,room temp,100%;(f)(i)oxalyl dichloride,DMF,CH 2Cl 2,0°C;(ii)R 4-NH 2,Et 3N,CH 2Cl 2,0°C,29%for 71,51%for 72;(g)NH 4OAc,NaIO 4,acetone,H 2O,room temp,39%for 26,71%for 25.Boronic Acid-Based Inhibitors Journal of Medicinal Chemistry,2009,Vol.52,No.92911in Table 1.We initially changed the Boc group of compound 6to a Cbz group (compound 17)(Table 2and Supporting Information Figure S2).Compound 17exhibited about 3-fold higher potency than compound 6.We also examined the activity of compound 18,in which the benzyloxy group of compound 17was replaced with a simple benzene ring,and the activity of 18(IC 50) 2.0µM)was about 2-fold higher than that of compound 17.By the mimicking of the partial structure of TSA (1),we introduced the dimethylamino group at the 4-position of the phenyl ring of compound 18,but compound 19displayed a 6.5-fold decrease in potency compared to the parent compound 18.Next,we converted the phenyl ring of compound 18to various heteroaryl rings.The 2-indole 23and 2-quinoline 24compounds exhibited HDAC-inhibitory activity less potent than that of the phenyl compound 18,whereas the 3-pyridine 20,5-thiazole 21,and 4-thiazole 22derivatives showed potencies similar to or greater than that of the phenyl compound 18(IC 50values:20)2.0µM,21)1.4µM,22)4.7µM),highlighting the importance of small ring size.To confirm the importance of R -amino acid structure,we examined the activity of malonic acid derivatives 25and 26in which the R -aminocarbonyl moiety of compounds 18and 20is replaced by the corresponding carboxamide (Table 2and Figure S2).Compounds 25and 26showed about 15-and 25-fold decreases in potency compared with the parent compounds 18and 20,respectively.Scheme 5aaReagents and conditions:(a)subtilisin,H 2O/DMF (1:3),37°C,42%for (R )-31,50%for (S )-32;(b)LiOH ·H 2O,EtOH,H 2O,room temp,100%;(c)biphenyl-3-ylamine,EDCI,HOBt,DMF,room temp,56-65%;(d)[Ir(cod)Cl]2,dppm,pinacolborane,CH 2Cl 2,room temp,79-82%;(e)HCl,AcOEt,CHCl 3,room temp,100%;(f)R 5-COOH,EDCI,HOBt,DMF,room temp,64-90%;(g)NH 4OAc,NaIO 4,acetone,H 2O,room temp,4-87%.Figure 1.(a)Proposed mechanism for the deacetylation of acetylated lysine substrates.(b)Proposed mechanism of inhibition of HDACs by boronic acids A .2912Journal of Medicinal Chemistry,2009,Vol.52,No.9Suzuki et al.Next we examined the influence of optical -pounds (R )-18,20,21and (S )-18,20,21were prepared and evaluated for their inhibitory effects on HDAC1,HDAC2,HDAC6,and HDAC8,as well as total HDACs from nuclear extracts.As shown in Table 3and Supporting Information Figure S3,in all cases,(S )-18,20,and 21were at least 10-fold more active than (R )-18,20,and 21,respectively.Since the stereochemistry of (S )-18,20,and 21is the same as that of natural lysine,these results suggest that these boronic acids act in the active site of HDACs.Among (S )-18,20,and 21,(S )-21was found to be the most potent pound (S )-21inhibited all HDACs with IC 50values in the micromolar or submicromolar range.Although (S )-21was less potent than SAHA (2),the isoform inhibition profile of (S )-21was similar to that of 2,which is the only HDAC inhibitor currently used in clinical practice.Cellular Assays.To examine the effectiveness of boronic acid-based HDAC inhibitors as anticancer drugs and tools for biological research,compounds (S )-18,20,and 21,as well as SAHA (2),were tested in a cancer cell growth inhibition assay.For initial screening,we used stomach cancer MKN45cells because HDAC inhibitors have been reported to inhibit the cell growth of MKN45cells.20The results are summarized in Ta-ble 4.SAHA (2)and its derivatives have been reported to show potent HDAC-inhibitory activity in enzyme assays and cancer cell growth inhibition assays.21However,a relatively large shift in potency between enzyme assay and cellular assay (GI 50/IC 50,abbreviated as potency shift in this paper)was observed with those hydroxamate HDAC inhibitors.21Indeed,as shown in Table 4,SAHA (2)exhibited a large potency shift in the cancerTable 1.HDAC Inhibitory Activity of Boronic Acids 5-16aaValues are the mean of at least three experiments.IC 50of SAHA (2)is 0.28µM.Table 2.HDAC Inhibitory Activity of 17-26aaValues are the mean of at least three experiments.Table 3.HDAC Inhibitory Activity of (S )-and (R )-18,20,21aIC 50(µM)class Icompd HDAC (nuclear extract)HDAC1HDAC2HDAC8class II,HDAC620.280.350.25 1.70.028(S )-18 1.6>10b 3.6>100 1.1(R )-1817>100>100>10024(S )-20 1.4 2.80.83230.32(R )-2015>10099>10014(S )-210.92 2.20.53 6.60.11(R )-2124>100>100>1005.6aValues are the mean of at least three experiments.b 38%inhibition at 10µM.Table 4.Growth-Inhibitory Activity on MKN45Cells and GI 50/IC 50Values of SAHA (2)and (S )-18,20,21aGI 50/IC 50compd GI 50(µM)HDAC HDAC1HDAC227.3262129(S )-189.3 5.8<0.93 2.6(S )-20 5.5 3.9 2.0 6.6(S )-213.53.81.66.6aValues are the mean of two separate experiments.Boronic Acid-Based InhibitorsJournal of Medicinal Chemistry,2009,Vol.52,No.92913cell growth inhibition assay using MKN45cells.22The reason for the large potency shift of SAHA (2)is unclear,but it seems reasonable to assume that it is at least partly due to poor membrane permeability resulting from the highly polar character of hydroxamic ing Advanced Chemistry Development (ACD/Laboratories)software,version 8.14for Solaris,the log D (pH 7)values of methylhydroxamic acid (CH 3CONHOH)and methylboronic acid (CH 3B(OH)2)were calculated to be -1.59and 1.0,respectively.The calculation results suggest that boronic acid is more lipophilic than hydroxamic acid under physiological conditions,and boronic acid derivatives might permeate through the cell membrane more efficiently than hydroxamates;there-fore,they might not show such large potency shifts as hydroxamates like SAHA (2).We then evaluated the growth-inhibitory activity of (S )-18,20,and 21on MKN45cells.As we expected,(S )-18,20,and 21inhibited the growth of MKN45cells and showed smaller potency shift values than SAHA (2).Among (S )-18,20,and 21,compound (S )-21showed the highest activity,being more potent than SAHA (2).Next,we evaluated growth inhibition by SAHA (2)and compound (S )-21against nine human cancer cell lines (Table 5).Compound (S )-21exerted potent growth inhibition against various human cancer cells,with GI 50values ranging from 0.73to 9.1µM,and these inhibitory activities were similar to those of SAHA (2)(average GI 50of (S )-21is 4.0µM,that of SAHA is 6.0µM).In addition,compound (R )-21did not show strong activity against these cancer cell lines (Table S1and Figure S4in Supporting Information)with GI 50s values ranging from 13to 21µM,suggesting the responsibility of HDAC inhibition for cancer cell growth repression.Next,we performed Western blot analysis to examine the HDAC-inhibitory effects of boronic acid derivatives in cells.Since nuclear HDACs such as HDAC 1and HDAC2catalyze the deacetylation of histones,3d the acetylation level of histone H4in human colon cancer HCT116cells was analyzed after treatment of the cells with compounds (S )-18,20,and 21.As can be seen in Figure 2,the level of acetylated histone H4was elevated dose-dependently.The level of acetylated R -tubulin was also investigated because (S )-18,20,and 21displayed potent inhibition of HDAC6,which is reported to catalyze the deacetylation of R -tubulin.23As expected,compounds (S )-18,20,and 21caused a dose-dependent increase in acetylation of R -tubulin.These results suggest that the cancer cell growth inhibition by boronic acids (S )-18,20,and 21was the result of HDAC inhibition.Molecular Modeling.Since the results of the enzyme assays (Table 3)suggested that boronic acids act within the active center of HDACs,we studied the binding mode of hydrated (S )-21within this site.We calculated the low energy conforma-tion of the hydrated (S )-21complex docked in a model based on the crystal structure of HDAC8(PDB code 1T67)using Macromodel 9.6software (Figure 3).An inspection of the complex shows that one of the oxygen atoms of the hydrated boronic acid can coordinate to the zinc ion (distance between oxygen and zinc,2.04Å)(Figure 3,left).In addition,the hydrogen of the OH group of Tyr 306is located 1.95and 2.20Åfrom the two oxygen atoms of the hydrated boronic acid,Table 5.Growth Inhibition of Various Cancer Cells Using SAHA (2)and (S )-21aGI 50(µM)cell2(S )-21HBC-5breast cancer17 6.5SNB-78central nervous system 169.1HCT116colon cancer 0.580.73DMS114lung cancer 2.9 2.4LOX-IMVI melanoma 1.3 1.3SK-OV-3ovarian cancer 2.5 2.2RXF-631L renal cancer 2.0 3.2MKN45stomach cancer 7.3 3.5PC-3prostate cancer 4.6 6.7mean6.04.0aValues arethe mean of two separate experiments.Figure 2.Western blot detection of acetylated R -tubulin and histone H4levels in HCT116cells after 8h treatment with (S )-18,20,21and reference compound 2.Figure 3.View of the conformation of (S )-21(ball-and-stick)docked in the HDAC8catalytic core.Residues within 5Åfrom the zinc ion are displayed in the tube graphic (left),and the surface of the enzyme is displayed in gray (right).2914Journal of Medicinal Chemistry,2009,Vol.52,No.9Suzuki et al.which suggests that Tyr306can form two hydrogen bonds with the hydrated boronic acid.Moreover,a short distance(2.22Å) between one of the hydrogens of the hydrated boronic acid and the nitrogen of His142was also observed.This indicates that hydrated boronic acids inhibit HDACs by interacting with the zinc ion,Tyr residue,and His residue in the active center.On the surface of HDAC8,the biphenyl ring is located in the hydrophobic region formed by the benzene rings of Tyr100 and Phe152and the alkyl chain of Lys33,and the thiazole ring lies in the hydrophobic area formed by the benzene ring of Tyr100and the methylene groups of Asp101,Gly151,and Phe208(Figure3,right).It is also suggested that two hydrogen bonds can be formed between the two NH groups and the carboxylate anion of Asp101(the distances are1.72and1.74Å).The observed interactions between(S)-21and HDAC8on the surface of the enzyme suggest the importance of the amino acid structure and the(S)-configuration of the inhibitor. ConclusionOn the basis of the proposed catalytic mechanism for the deacetylation of acetylated lysine substrates by HDACs,we designed a series of boronic acids bearing an R-amino acid moiety as candidate mechanism-based HDAC inhibitors.Among the synthesized compounds,compounds(S)-18,20,and21 displayed potent HDAC-inhibitory activities,suggesting that these boronic acids act in the active site of pounds (S)-18,20,and21also showed cancer cell growth-inhibitory activities as potent as SAHA(2).Intracellular HDAC inhibition by compounds(S)-18,20,and21was confirmed by Western blot analysis of acetylated histone H4and acetylated R-tubulin.A molecular modeling study of the HDAC8/(S)-21complex suggested that the hydrated boronic acid interacts with zinc ion, Tyr residue,and His residue in the active site of HDACs. Thus,we have identified a novel lead structure from which it should be possible to develop more potent HDAC inhibitors. Although boronic acids have been used as inhibitors for various hydrolytic enzymes such as serine protease,24arginase,25and proteasome,26this is thefirst report of HDAC inhibitors containing a boronic acid moiety.The results obtained in this study suggest that boronic acid-based inhibitors of HDACs have considerable potential for the development of novel therapeutic agents and tools for biological research.Experimental SectionChemistry.Melting points were determined using a Yanagimoto micro melting point apparatus or a Bu¨chi545melting point apparatus and were left uncorrected.Proton nuclear magnetic resonance spectra(1H NMR)and carbon nuclear magnetic resonance spectra(13C NMR)were recorded with a JEOL JNM-LA500,JEOL JNM-A500,or Bruker Avance600spectrometer in solvents as indicated.Chemical shifts(δ)are reported in parts per million relative to the internal standard tetramethylsilane.Elemental analysis was performed with a Yanaco CHN CORDER NT-5analyzer,and all values were within(0.4%of the calculated values,which indicates>95%purity of the tested compounds.Fast atom bombardment(FAB)mass spectra were recorded on a JEOL JMS-SX102A mass spectrometer.In positive-mode MS analysis using 3-nitrobenzyl alcohol(NBA)as a matrix,boronic acids are esterified with NBA and the molecular weight detected corresponds to(M+2NBA-2H2O+H)+or(M+2NBA-2H2O)+.In negative-mode analysis using glycerol(Gly)as a matrix,the molecular weight detected corresponds to(M+Gly-2H2O-H)-.HPLC was performed with a Shimazu instrument equipped with a CHIRALPAK IA column(4.6mm×250mm,Daicel Chemical Industries),and the samples eluted at1mL/min with ethanol and n-hexane.Reagents and solvents were purchased from Aldrich,Tokyo Kasei Kogyo,Wako Pure Chemical Industries,and Kanto Kagaku and used without purification.Flash column chromatog-raphy was performed using silica gel60(particle size0.046-0.063 mm)supplied by Merck.6-tert-Butoxycarbonylamino-7-oxo-7-phenylaminoheptylbo-ronic Acid(5).Step1:Preparation of Diethyl2-tert-Butoxy-carbonylaminomalonate(28).To a suspension of diethyl ami-nomalonate(27;10.0g,47.2mmol)and Et3N(32.9mL,236mmol) in THF(20mL)was added a solution of(Boc)2O(20.6g,94.4 mmol)in THF(10mL),and the solution was stirred overnight at room temperature.The reaction mixture was poured into water and extracted with AcOEt.The AcOEt layer was washed with water and brine and dried over Na2SO4.Filtration and concentration in vacuo and purification by silica gelflash column chromatography (AcOEt/n-hexane)1/5)gave10.5g(81%)of28as a colorless oil:1H NMR(CDCl3,500MHz,δ,ppm)5.56(1H,d,J)6.7Hz), 4.95(1H,d,J)7.6Hz),4.27(4H,m),1.45(9H,s),1.30(6H,t, J)7.3Hz).Step2:Preparation of Diethyl2-tert-Butoxycarbonylamino-2-(penten-4-yl)malonate(29).To a solution of28(10.2g,37.2 mmol)obtained above in EtOH(15mL)was added NaOEt(2.78 g,40.9mmol)under Ar gas at0°C.The reaction mixture was stirred at0°C for7min.After that,to the solution was added 5-bromopent-1-ene(8.32g,55.8mmol),and the mixture was refluxed for10h.It was then poured into water and extracted with AcOEt.The AcOEt layer was washed with water and brine and dried over Na2SO4.Filtration and concentration in vacuo and purification by silica gelflash column chromatography(AcOEt/n-hexane)1/6)gave11.3g(89%)of29as a colorless oil:1H NMR (CDCl3,500MHz,δ,ppm)5.94(1H,broad s),5.76(1H,ddt,J) 17,10,6.4Hz),5.00(1H,dd,J)15,1.8Hz),4.95(1H,d,J)10 Hz),4.26-4.18(4H,m),2.28(2H,m),2.07(2H,q,J)7.3Hz), 1.43(9H,s),1.30-1.19(8H,m).Step3:Preparation of2-tert-Butoxycarbonylamino-2-(ethoxy-carbonyl)hept-6-enoic Acid(30).To a solution of29(11.3g,33.0 mmol)obtained above in EtOH/H2O(20mL/10mL)was added LiOH·H2O(1.52g,36.3mmol),and the solution was stirred overnight at0°C.The reaction mixture was neutralized with10% citric acid and extracted with AcOEt.The AcOEt layer was washed with brine and dried over Na2SO4.Filtration and concentration in vacuo gave10.3g(99%)of30as a yellow oil:1H NMR(CDCl3, 500MHz,δ,ppm)5.80-5.71(2H,m),5.01(1H,dd,J)17,1.5 Hz),4.97(1H,dd,J)10,1.8Hz),4.31-4.18(2H,m),2.22(2H, m),2.07(2H,m),1.44(9H,s),1.39-1.22(5H,m).Step4:Preparation of Ethyl2-tert-Butoxycarbonylamino-hept-6-enoate(31).A solution of30(10.3g,32.6mmol)obtained above in toluene(40mL)was refluxed for9h.The reaction mixture was concentrated and purified byflash column chromatography (AcOEt/n-hexane)1/6)to give8.51g(94%)of31as a yellow oil:1H NMR(CDCl3,500MHz,δ,ppm)5.77(1H,ddt,J)17, 10,6.7Hz),5.04-4.94(3H,m),4.28(1H,m),4.19(2H,m),2.07 (2H,m),1.81(1H,m,),1.63(1H,m),1.53-1.37(11H,m),1.28 (3H,t,J)7.3Hz).Step5:Preparation of2-tert-Butoxycarbonylaminohept-6-enoic Acid(32).To a solution of31(8.34g,30.8mmol)obtained above in EtOH/H2O(20mL/10mL)was added LiOH·H2O(1.25 g,29.8mmol),and the solution was stirred overnight at0°C.The reaction mixture was neutralized with10%citric acid and extracted with AcOEt.The AcOEt layer was washed with brine and dried over Na2SO4.Filtration and concentration in vacuo gave7.01g (94%)of32as a white solid:1H NMR(CDCl3,500MHz,δ,ppm) 5.78(1H,ddt,J)17,10,6.7Hz),5.06-4.94(3H,m),4.32(1H, m),2.09(2H,m),1.87(1H,m),1.68(1H,m),1.57-1.37(11H, m).Step6:Preparation of tert-Butyl1-(Phenylaminocarbonyl) hex-5-en-1-ylcarbamate(33).To a solution of32(1.00g,4.11 mmol)and aniline(560µL,6.17mmol)in DMF(15mL)were added1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochlo-ride(EDCI;1.18g,6.17mmol)and1-hydroxy-1H-benzotriazole monohydrate(HOBt·H2O;834mg,6.17mmol),and the mixture was stirred overnight at room temperature.The reaction mixtureBoronic Acid-Based Inhibitors Journal of Medicinal Chemistry,2009,Vol.52,No.92915。

商陆的化学成分与药理作用研究进展及质量标志物的预测分析

商陆的化学成分与药理作用研究进展及质量标志物的预测分析

商陆的化学成分与药理作用研究进展及质量标志物的预测分析黄宏威,刘传鑫,颜昌钖,肖治均,李玮,孔娇,李梦雨,王小雨,付婷婷,姚孟欣,张晨宁*[摘要]商陆是中国传统的中药材,近年来,对商陆的研究逐渐深入,其有效成分及药理作用倍受关注,在治疗多种疾病方面具有广泛的应用前景。

商陆主要含有的化学成分包括三萜皂苷、多糖、黄酮和酚酸等,现代药理学研究发现其具有利尿、调节免疫、祛痰等作用。

在此研究基础上,根据中药质量标志物的定义,本文从传统功效、传统药性、临床新用途、可测成分、炮制前后成分变化及入血成分等几个方面对商陆的质量标志物进行预测分析,为商陆质量评价研究提供科学依据。

[关键词]商陆;化学成分;药理作用;质量标志物;质量控制[中图分类号]R284[文献标志码]A[文章编号]1674-0440(2020)03-0188-11DOI:10.13220/ki.jipr.2020.03.004Chemical constituents and pharmacological effects of Phytolaccae Radix and prediction of quality markers:research advancesHUANG Hong-wei,LIU Chuan-xin,YAN Chang-yang,XIAO Zhi-jun,LI Wei,KONG Jiao,LI Meng-yu,WANG Xiao-yu,FU Ting-ting,YAO Meng-xin,ZHANG Chen-ning*(College of Chinese Medicine,Beijing University of Chinese Medicine,Beijing100029,China)[Abstract]Phytolaccae Radix is a traditional Chinese herbal medicine.In recent years,its study has gradually been deep⁃ened,and its effective ingredients and pharmacological effects have attracted much attention,and it has broad application prospects in the treatment of various diseases.Phytolaccae Radix mainly contains triterpenoid saponins,polysaccharides,flavonoids,phenolic ac⁃ids and other components.According to modern pharmacological studies,it has diuretic,immunomodulatory and expectorant effects. On the basis of the studies,and according to the definition of quality marker(Q-marker),we predict its Q-markers from the aspects of the traditional efficacy,traditional medicinal properties,new clinical use,measurable composition,composition changes before and after processing,the plasma composition,and so on,which provides a scientific basis for the quality evaluation of Phytolaccae Radix.[Key words]Phytolaccae Radix;chemical compositions;pharmacological effects;quality marker(Q-marker);quality control中药商陆(Phytolaccae Radix)为商陆科植物商陆(Phytolacca acinosa Roxb.)或垂序商陆(P.ameri⁃cana L.)的干燥根。

翻译

翻译

天然产物杂志从对细胞死亡敏感和抗癌细胞系列中的海绵生物中提取抗恶性细胞增值活性的二萜异腈的评价人名和通讯地址等等暂不翻译背景信息摘要:一个新的在1位的和在已知2,4位的腈基的二萜,是从加勒比海海绵Pseudoaxinella在人类体外癌症细胞使用的线检MTT比色法检测和定量和电子扫描显微镜中分离出来的。

化合物14显示的为人类的PC3前列腺凋亡敏感的肿瘤细胞系的活动,。

化合物3和4表现出类似的增长抑制个人为三个APOP凋亡敏感和3个抗凋亡的肿瘤细胞株的定量电子显微镜分析表明,化合物1和2施加他们的活动,通过细胞毒性个人ECTS 通过抑制细胞生长的个人ECTS化合物3和4。

这些结果确定潜在的铅化合物对海洋中二萜异腈抗癌药物的发现。

萜类化合物,包含异氰和异硫氰团体往往在海洋无脊椎动物中发现的次生代谢产物,例如海绵等在过去的15年,海洋天然产物因为他们的生物学活性乎寻常的异类功能化,在科学界很多成员引起了广泛的兴趣,事实上,一个最有力的海洋抗疟药化合物是最初分离的二萜异腈,从热带海绵状物,特点是由amphilectane骨架。

在我们的研究项目的框架中, 被认为是新颖的先导化合物可以视作典型的抗癌试验,加勒比海的海绵化学海绵伪黄色生物进行了研究。

本研究引发了分离了一个二萜异腈化合物(1)和三个已知的类似的(24), 因为不同的数目和位置的异腈官能团和双键,所有这一切都是紧密的联系的。

用比色MTT检测评价生长抑菌浓度IC50(即全球经济增长的一个给定的细胞参与增殖培养了三天的化合物减少50%的浓度)的不同双萜的浓度体外测试。

定量的电子显微镜(即计算捷尔- 辅助相衬显微镜)将被用来检测是否影响细胞性通过细胞毒性或抑制细胞生长的途径。

我们已经成功地完成例如其他类型的化合物的特点包括真菌次级代谢产物, 类固醇治疗,Amar——和yllidaceae生物碱2007 Pawlik在大巴哈马海岸考察的海绵Pseudoaxinella蔺沿的(甜味剂礁)的样品被切成被冻结的小块样本然后运送到实验室用MeOH和CHCl3分别萃取提纯。

盐酸倍他司汀及其关键中间体的合成综述

盐酸倍他司汀及其关键中间体的合成综述

盐酸倍他司汀及其关键中间体的合成综述盐酸倍他司汀(Escitalopram hydrobromide)是一种常用的抗抑郁药物,广泛用于治疗抑郁症和焦虑症。

它是一种选择性去甲肾上腺素再摄取抑制剂(SSRI),能有效增加大脑中去甲肾上腺素的水平,从而改善情绪和心理状态。

盐酸倍他司汀的合成工艺涉及多个中间体的合成步骤,下面将从中间体入手,对盐酸倍他司汀及其关键中间体的合成进行综述。

一、关键中间体的合成1. 3-氯-3-(二氯甲基)丙烯(3-Chloro-3-(dichloromethyl)propene)3-氯-3-(二氯甲基)丙烯是合成盐酸倍他司汀的关键中间体之一,它通常通过氯乙腈和三氯乙酸的反应制备。

首先将氯乙腈和三氯乙酸在二氯甲烷中反应,再加入三甲胺,使用活性碳吸附,最后蒸馏得到3-氯-3-(二氯甲基)丙烯。

2. 3-(二氯甲基)-7-氟-1,3-二氢-5-(4-甲基-1-哌啶基)-2H-1,4-苯并二氮在-3-酮(3-(Dichloromethyl)-7-fluoro-1,3-dihydro-5-(4-methyl-1-piperazinyl)-2H-1,4-be nzodiazepin-2-one)以上述3-氯-3-(二氯甲基)丙烯为起始原料,通过串联反应得到3-(二氯甲基)-7-氟-1,3-二氢-5-(4-甲基-1-哌啶基)-2H-1,4-苯并二氮在-3-酮。

将3-氯-3-(二氯甲基)丙烯和对氨基苯甲酮在三甲苯中加热反应,生成中间体,再用氢醌处理,发生串联反应,得到目标产物。

3. 盐酸倍他司汀通过将3-(二氯甲基)-7-氟-1,3-二氢-5-(4-甲基-1-哌啶基)-2H-1,4-苯并二氮在-3-酮与盐酸的反应,得到盐酸倍他司汀的合成。

二、盐酸倍他司汀的合成综述盐酸倍他司汀的合成工艺包括多个中间体的合成步骤,其合成路线如下:以上合成路线中间体的合成步骤相对繁琐,需要多步反应和纯化过程,针对每个中间体的合成过程进行优化是十分重要的。

药用辅料中英文对照

药用辅料中英文对照

药用辅料中英文对照1 阿拉伯胶(Acacia)2 乙酰舒泛钾(Acesulfame Potassium)3 冰醋酸(Acetic Acid,Glacial)4 乙酰枸橼酸三丁酯(AcetyltributylCitrate)5 乙酰枸橼酸三乙酯(AcetyltriethylCitrate)6 人血白蛋白(Albumin)7 乙醇(Ethanol)8 海藻酸(Alginic Acid)9 脂肪族聚酯(Aliphatic Polyesters)10 阿力糖(Alitame)11 杏仁油(Almond Oil)12 维生素E(Alpha Tocopherol)13 氨溶液(Ammonia Solution)14 维生素C(Ascorbic Acid)15 棕榈酸维生素C酯(Ascorbyl Palmitate)16 阿司帕坦(Aspartame)17 绿坡缕石(Attapulgite)18 皂土(Bentonite)19 苯扎氯铵(Benzalkonium Chloride)20 苄索氯铵(Benzethonium Chloride)21 苯甲酸(Benzoic Acid)22 苯甲醇(Benzyl Alcohol)23 苯甲酸苄酯(Benzyl Benzoate)24 溴硝丙二醇(Bronopol)25 丁羟茴醚(Butylated Hydroxyanisole)26 丁羟甲苯(Butylated Hydroxytoluene)27 羟苯丁酯(Butylparaben)28 碳酸钙(Calcium Carbonate)29 无水磷酸氢钙(Calcium Phosphate,Dibasic Anhydrous)30 磷酸氢钙二水合物(Calcium Phosphate,Dibasic Dihydrate)31 磷酸钙(Calcium Phosphate,Tribasic)32 硬脂酸钙(Calcium Stearate)33 硫酸钙(Calcium Sulfate)34 低芥酸菜籽油(Canola Oil)35 卡波姆(Carbomer)36 二氧化碳(Carbon Dioxide)37 羧甲纤维素钙(Carboxymethylcellulose Calcium)38 羧甲纤维素钠(Carboxymethylcellulose Sodium)39 角叉菜胶(Carrageenan)40 蓖麻油(Castor Oil)41 氢化蓖麻油(Castor Oil,Hydro-genated)42 微晶纤维素(Cellulose,Microcrystalline)43 粉状纤维素(Cellulose,Powdered)44 微粉硅胶微晶纤维素(Cellulose, Silicified Microcrystalline)45 醋酸纤维素(Cellulose Acetate)46 纤维醋法酯(Cellulose Acetate Phthalate)47 角豆胶(Ceratonia)48 十八十六醇(Cetostearyl Alcohol)49 西曲溴铵(Cetrimide)50 十六醇(Cetyl Alcohol)51 壳聚糖(Chitosan)52 氯己定(Chlorhexidine)53 三氯叔丁醇(Chlorobutanol)54 氯甲酚(Chlorocresol)55 一氯二氟乙烷(Chlorodifluoroe-thane)56 氟里昂(Chlorofluorocabons)57 对氯间二甲酚(Chloroxylenol)58 胆固醇(Cholesterol)59 枸橼酸(Citric Acid Monohydrate)60 胶态二氧化硅(微粉硅胶)(Colloidal Silicon Dioxide)61 着色剂(Coloring Agents)62 玉米油(Corn Oil)63 棉籽油(Cottonseed Oil)64 甲酚(Cresol)65 交联羧甲纤维素钠(Croscarmellose Sodium)66 交联聚维酮(Crospovidone)67 环糊精(Cyclodextrins)68 环甲基硅酮(Cyclomethicone)69 苯甲地那铵(Denatonium Benzoate)70 葡萄糖结合剂(Dextrates)71 糊精(Dextrin)72 葡萄糖(Dextrose)73 邻苯二甲酸二丁酯(Dibutyl Phthalate)74 癸二酸二丁酯(Dibutyl Sebacate)75 二乙醇胺(Diethanolamine)76 邻苯二甲酸二乙酯(Diethyl Phthalate)77 二氟乙烷(Difluoroethane)78 二甲硅油(Dimethicone)79 二甲醚(Dimethyl Ether)80 邻苯二甲酸二甲酯(Dimethyl Phthalate)81 二甲亚砜(Dimethyl Sulfoxide)82 多库酯钠(Docusate Sodium)83 依地酸(乙二胺四乙酸)(Edetic Acid)84 乙酸乙酯(Ethyl Acetate)85 乙基麦芽酚(Ethyl Maltol)86 油酸乙酯(Ethyl Oleate)87 乙基香草醛(Ethyl Vanillin)88 乙基纤维素(Ethylcellulose)89 硬脂酸棕榈酸乙二醇酯(Ethylene Glycol Palmitostearate)90 羟苯乙酯(Ethylparaben)91 果糖(Fructose)92 富马酸(Fumaric Acid)93 明胶(Gelatin)94 液体葡萄糖(Glucose,Liquid)95 甘油(Glycerin)96 山萮酸甘油酯(Glyceryl Behenate)97 单油酸甘油酯(Glyceryl Monooleate)98 单硬脂酸甘油酯(Glyceryl Monostearate)99 硬脂酸棕榈酸甘油酯(Glyceryl Palmitostearate)100 四氢呋喃聚乙二醇醚(Glycofurol)101 瓜耳胶(Guar Gum)102 七氟丙烷(HFC)(Heptafluoro-propane)103 海克西定(Hexetidine)104 烷烃类(HC) (Hydrocarbons)105 盐酸(Hydrochloric Acid)106 羟乙纤维素(Hydroxyethyl Cellulose)107 羟乙甲纤维素(Hydroxyethylmethyl Cellulose)108 羟丙纤维素(Hydroxypropyl Cellulose)109 低取代羟丙纤维素(Hydroxypropyl Cellulose,Low-substituted) 110 羟丙甲纤维素(Hypromellose)111 羟丙甲纤维素酞酸酯(Hypromellose Phthalate)112 咪唑烷脲(Imidurea)113 异丙醇(Isopropyl Alcohol)114 肉豆蔻酸异丙酯(Isopropyl Myristate)115 棕榈酸异丙酯(Isopropyl Palmitate)116 白陶土(Kaolin)117 乳酸(Lactic Acid)118 拉克替醇(Lactitol)119 乳糖(Lactose)120 羊毛脂(Lanolin)121 含水羊毛脂(Lanolin,Hydrous)122 羊毛醇(Lanolin Alcohols)123 卵磷脂(Lecithin)124 硅酸镁铝(Magnesium Aluminum Silicate)125 碳酸镁(Magnesium Carbonate)126 氧化镁(Magnesium Oxide)127 硅酸镁(Magnesium Silicate)128 硬脂酸镁(Magnesium Stearate)129 三硅酸镁(Magnesium Trisilicate)130 苹果酸(Malic Acid)131 麦芽糖醇(Maltitol)132 麦芽糖醇溶液(Maltitol Solution)133 麦芽糖糊精(Maltodextrin)134 麦芽酚(Maltol)135 麦芽糖(Maltose)136 甘露醇(Mannitol)137 中链脂肪酸甘油三酯(Medium-chain Triglycerides)138 葡甲胺(Meglumine)139 薄荷脑(Menthol)140 甲基纤维素(Methylcellulose)141 羟苯甲酯(Methylparaben)142 液体石蜡(Mineral Oil)143 轻质液体石蜡(Mineral Oil,Light)144 液体石蜡羊毛醇(Mineral Oil and Lanolin Alcohols)145 单乙醇胺(Monoethanolamine)146 谷氨酸一钠(Monosodium Glutamate)147 硫代甘油(Monothioglycerol)148 氮(Nitrogen)149 一氧化二氮(Nitrous Oxide)150 油酸(Oleic Acid)151 橄榄油(Olive Oil)152 石蜡(Paraffin)153 花生油(Peanut Oil)154 凡士林(Petrolatum)155 凡士林羊毛醇(Petrolatum and Lanolin Alcohols)156 苯酚(Phenol)157 苯氧乙醇(Phenoxyethanol)158 苯乙醇(Phenylethyl Alcohol)159 醋酸苯汞(Phenylmercuric Acetate)160 硼酸苯汞(Phenylmercuric Borate)161 硝酸苯汞(Phenylmercuric Nitrate)162 磷酸(Phosphoric Acid)163 波拉克林钾(Polacrilin Potassium)164 泊洛沙姆(Poloxamer)165 葡聚糖(Polydextrose)166 聚乙二醇(Polyethylene Glycol)167 聚氧乙烯(Polyethylene Oxide)168 聚(甲基)丙烯酸树脂(Polymethacr-ylates)169 聚氧乙烯烷基醚(Polyoxyethylene Alkyl Ethers)170 聚氧乙烯蓖麻油衍生物(Polyoxyeth-ylene Castor Oil Derivatives) 171 聚山梨酯(Polyoxyethylene Sorbitan Fatty Acid Esters)172 硬脂酸聚氧乙烯酯(Polyoxyethylene Stearates)173 聚醋酸乙烯酞酸酯(Polyvinyl Acetate Phthalate)174 聚乙烯醇(Polyvinyl Alcohol)175 苯甲酸钾(Potassium Benzoate)176 碳酸氢钾(Potassium Bicarbonate)177 氯化钾(Potassium Chloride)178 枸橼酸钾(Potassium Citrate)179 氢氧化钾(Potassium Hydroxide)180 焦亚硫酸钾(Potassium Metabisulfite)181 山梨酸钾(Potassium Sorbate)182 聚维酮(Povidone)183 丙酸(Propionic Acid)184 没食子酸丙酯(Propyl Gallate)185 碳酸丙烯酯(Propylene Carbonate)186 丙二醇(Propylene Glycol)187 海藻酸丙二醇酯(Propylene Glycol Alginate)188 羟苯丙酯(Propylparaben)189 糖精(Saccharin)190 糖精钠(Saccharin Sodium)191 芝麻油(Sesame Oil)192 虫胶(Shellac)193 二氧化硅二甲硅油(Simethicone)194 海藻酸钠(Sodium Alginate)195 抗坏血酸钠(Sodium Ascorbate)196 苯甲酸钠(Sodium Benzoate)197 碳酸氢钠(Sodium Bicarbonate)198 氯化钠(Sodium Chloride)199 枸橼酸钠二水合物(Sodium Citrate Dihydrate)200 环拉酸钠(Sodium Cyclamate)201 氢氧化钠(Sodium Hydroxide)202 月桂硫酸钠(十二烷基硫酸钠)(Sodium Lauryl Sulfate)203 焦亚硫酸钠(偏亚硫酸钠)(Sodium Metabisulfite)204 磷酸氢二钠(Sodium Phosphate,Dibasic)205 磷酸二氢钠(Sodium Phosphate ,Monobasic)206 丙酸钠(Sodium Propionate)207 羧甲淀粉钠(Sodium Starch Glycolate)208 硬脂富马酸钠(Sodium Stearyl Fumarate)209 山梨酸(Sorbic Acid)210 山梨坦酯Sorbitan Esters(Sorbitan Fatty Acid Esters) 211 山梨醇(Sorbitol)212 大豆油(Soybean Oil)213 淀粉(Starch)214 预胶化淀粉(Starch,Pregelatinized)215 灭菌玉米淀粉(Starch,Sterilizable Maize)216 硬脂酸(Stearic Acid)217 硬脂醇(Stearyl Alcohol)218 羟糖氯(Sucralose)219 蔗糖(Sucrose)220 可压性蔗糖(Sugar,Compressible)221 蔗糖粉(Sugar,Confectioner’s)222 蔗糖球形颗粒(Sugar Spheres)223 硫酸(Sulfuric Acid)224 葵花籽油(Sunflower Oil)225 氢化植物油(硬脂)栓剂基质(Sup-pository Bases,Hard Fat) 226 滑石粉(Talc)227 酒石酸(Tartaric Acid)228 四氟乙烷(HFC)(Tetrafluoroe-thane)229 硫柳汞(Thimerosal)230 二氧化钛(Titanium Dioxide)231 西黄蓍胶(Tragacanth)232 海藻糖(Trehalose)233 三醋汀(Triacetin)234 枸橼酸三丁酯(Tributyl Citrate)235 三乙醇胺(Triethanolamine)236 枸橼酸三乙酯(Triethyl Citrate)237 香草醛(Vanillin)238 氢化植物油(Vegetable Oil,Hydrogenated)239 纯化水(Water)240 阴离子乳化蜡(Wax,Anionic Emulsifying)241 巴西棕榈蜡(Wax,Carnauba)242 十六醇酯蜡(Wax,Cetyl Esters)243 微晶蜡(Wax,Microcrystalline)244 非离子乳化蜡(聚西托醇乳化蜡)(Wax,Nonionic Emulsifying) 245 白蜡(Wax,White)246 黄蜡(Wax,Yellow)247 黄原酸胶(Xanthan Gum)248 木糖醇(Xylitol)796249 玉米朊(玉米蛋白)(Zein)250 硬脂酸锌(Zinc Stearate)。

抗过敏药和抗溃疡药

抗过敏药和抗溃疡药

抗过敏药和抗溃疡药组胺〔Histamine〕是一种内源性的生物活性物质,可参与多种复杂的生理过程,组胺的化学名为4(5)-(2-氨乙基)咪唑。

这一章的要紧内容原是与组胺拮抗有关的药物,作用于组胺H1受体,产生抗过敏活性,作用于组胺H2受体,产生抗溃疡活性。

由于近年来抗溃疡药物开展对比快,已不止抗组胺一种途径,因此本章的题目相应修改为抗过敏药和抗溃疡药。

组胺(Histamine)广泛存在于自然界多种植物、动物和微生物体内,是组氨酸〔Histidine〕在组氨酸脱羧酶〔Histidinedecarboxylase〕催化下脱羧形成的。

在动物体内组胺是一种重要的化学递质,在细胞之间传递信息,参与一系列复杂的生理过程。

目前发觉的组胺受体有3个亚型,分不称为H1受体、H2受体和H3受体。

组胺的生物活性作用受体组织作用H1 肠、子宫、支气管、尿道、膀胱平滑肌毛细血管大脑收缩松弛失眠〔唤醒〕H2胃导气管和血管平滑肌心脏免疫活性细胞酸分泌松弛正性变时和变力效应抑制细胞功能H3 脑肺抑制组胺的合成与释放抑制组胺的合成与释放以及神经元的收缩当外源性物质〔如食物、动物毛发、花粉、灰尘和某些多糖或蛋白质类的抗原或变应原〕对人体能引起变态性或过敏性反响〔常见的有枯草热、瘙痒、接触性皮炎以及过敏性哮喘和休克等〕,这已证实与体内组胺释放有关,故H1受体选择性拮抗剂已被广泛用作抗过敏药。

第一节组胺H1受体拮抗剂和抗过敏药组胺作用于H1-受体,引起肠道、子宫、支气管等器官的平滑肌收缩,严峻时导致支气管平滑肌痉挛而呼吸困难。

另外还引起毛细血管舒张,导致血管壁渗透性增加,产生水肿和痒感,参与变态反响的发生。

组胺H1-受体的兴奋是导致变态反响性疾病的要紧缘故之一,阻断其在体内的作用就具有抗变态反响的药理活性。

H1-受体拮抗剂结构类型可分为氨基醚类、乙二胺类、哌嗪类、丙胺类、三环类及哌啶类。

1、氨基醚类盐酸苯海拉明〔Diphenhydraminehydrochloride〕为本类药物的典型代表,盐酸苯海拉明的分子中含有一个氧原子和一个氮原子,两原子之间间隔两个碳原子,因此被称为氨基醚类抗组胺药物。

圣和散对神经胶质瘤细胞DNA放射损伤修复的抑制作用(英文)

圣和散对神经胶质瘤细胞DNA放射损伤修复的抑制作用(英文)
有 弱的收敛及 抑菌作用 , 以薄荷脑 加强清 热解毒 、 ] 佐
[ ] 占红 , 权. 1徐 景少 甘石冰 脑洗剂外涂对荨麻疹 瘙痒 的止痒作用临 床观察 [j 现代 中医药 ,0 0 3 ( )2 . J. 2 1 ,0 2 :5
[] 2杨锡平 , 胡一江 , 姜剑雄 . 生漆诱导过敏 }接触性皮 炎兔模型的建 生 立及敏灵液疗效的初探[] J 上海实验动物学 ,022 () 06. . 20 , 1: —1 2 6 [] 3马拴全 , 李伟 , 王用峰 , 甘石冰脑冼剂抗炎 、 等. 止痒作用的动物实
验研究 [ ] 中华中医药学会皮肤科分会第七次学术年会 、0 0 C. 2 1
消肿止痛之功 , 薄荷脑能选择性地刺激人体皮肤或黏 膜的冷觉感受器 , 产生冷觉反射和冷感 , 引起皮肤黏 膜血管收缩( 实际上皮肤保持正常 ) , 外用可 以消炎 、 止痛、 止痒 , 促进血液循环 , 减轻浮肿等。 此外 , 冰片和
Abtat Obet e T vlaeteihbt nfnt no h nh o dr( H o N a g e a n f l ma src j ci :oeaut n iio u ci f e g epw e S P)n D A dmaerpi go i v h i o S i r go
实 验 中 医 药 学
硎 ≯ 晦 露混学诼
2 011年 第 1 卷 2 第 5期
是 其止痒 的机理之一 , 为其止痒 提供 了实验 依据 。
作用主要是收湿敛疮止痒 , 加入冰片、 薄荷脑加强 了 其清凉、 解毒 、 止痒之力 , 并取其芳香开窍、 辛香透达 作用提高透皮吸收能力 , 更增强了药效。
Wa gHu n , n in u 2Ho e g i3 n a Wa g Ja h a , u Z n xa

中医药治疗糖尿病酮症酸中毒的研究进展

中医药治疗糖尿病酮症酸中毒的研究进展

屮医药治疗糖尿病酮症酸屮毒的研究进展熊佳重庆市九龙坡区中医院脾胃病科,重庆400080[摘要]糖尿病酮症酸中毒(DKA冤是糖尿病患者的急性并发症之一,病情急、发展快,若不及时诊治,可出现昏迷、休克,甚至危及患者生命。

DKA为消渴病的进一步加重,中医很早就已经认识了消渴病的病因病机,并流传了很多经典方剂及中药。

本文收集近5年相关文献,梳理和分析DKA中医治疗及现代研究,就DKA中医分型论治、中药现代制剂及药理的研究进展作一综述,以期为DKA的中医临床治疗提供重要信息。

[关键词]中医药;治疗;糖尿病酮症酸中毒;研究进展;中药制剂冲图分类号]R587.2[文献标识码]A[文章编号]1674-4721(2021)6(b)-0039-04Research progress of traditional Chinese medicine in treating diabetic ke­toacidosisXIONG JiaDeparLmenL of Spleen and SLomach Disease,Jiulongpo Traditional Chinese Medicine Hospital of Chongqing CiLy, Chongqing400080,China[Abstract]DiabeLic keLoacidosis(DKA)is one of Lhe acuLe complications of diabeLic paLienLs.The disease is acuLe and develops rapidly.WiLhouL Limely diagnosis and LreaLmenL,iL may lead Lo coma,shock,or even endanger Lhe paLienLs' lives.DKA is a furLher aggravaLion of diabeLes disease.TradiLional Chinese medicine has earlier recognized Lhe eLiology and paLhogenesis of diabeLes,and many classic prescripLions and LradiLional Chinese medicine have been spread.This arLicle collecLs relevanL liLeraLure in Lhe pasL5years,sorLs ouL and analyzes DKA Chinese medicine LreaLmenL and mod­ern research,summarizes Lhe research progress of DKA classificaLion and LreaLmenL,modern Chinese medicine prepara­Lions and pharmacology,in order Lo provide imporLanL informaLion for Lhe clinical LreaLmenL of DKA in LradiLional Chi­nese medicine.[Key words]TradiLional Chinese medicine;TreaLmenL;DiabeLic keLoacidosis;Research progress;TradiLional Chinese medicine preparaLion糖尿病酮症酸中毒(diabetic ketoacidosis,DKA)是在胰岛素严重缺乏的情况下出现的危及生命的急症,严重高血糖、脂肪分解代谢增加和脂肪酸过度氧化会生成酮体,由此引起机体代谢性酸中毒、脱水、体液丢失及电解质紊乱,病情严重者可出现昏迷、休克,甚至危及患者生命叫DKA的主要症状包括恶心呕吐、口渴多尿、腹痛、呼吸急促,体征包括心动过速、黏膜干燥或皮肤弹性下降、脱水或低血压、呼吸急促或呼吸抑制或Kussmaul呼吸(是DKA的标准症状)、腹部压痛、昏睡或反应迟钝或脑水肿或昏迷,结合实验室检查结果可以明确DKA诊断罠中医药治疗对于改善DKA症状、提高临床疗效、预防再次发作具有独特的优势。

世界卫生组织儿童标准处方集

世界卫生组织儿童标准处方集

WHO Model Formulary for ChildrenBased on the Second Model List of Essential Medicines for Children 2009世界卫生组织儿童标准处方集基于2009年儿童基本用药的第二个标准目录WHO Library Cataloguing-in-Publication Data:WHO model formulary for children 2010.Based on the second model list of essential medicines for children 2009.1.Essential drugs.2.Formularies.3.Pharmaceutical preparations.4.Child.5.Drug utilization. I.World Health Organization.ISBN 978 92 4 159932 0 (NLM classification: QV 55)世界卫生组织实验室出版数据目录:世界卫生组织儿童标准处方集基于2009年儿童基本用药的第二个标准处方集1.基本药物 2.处方一览表 3.药品制备 4儿童 5.药物ISBN 978 92 4 159932 0 (美国国立医学图书馆分类:QV55)World Health Organization 2010All rights reserved. Publications of the World Health Organization can be obtained fromWHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: ******************). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the aboveaddress(fax:+41227914806;e-mail:*******************).世界卫生组织2010版权所有。

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects

DOI: 10.1126/scitranslmed.3002842, 95ra73 (2011);3 Sci Transl Med , et al.Michael Kalos and Can Establish Memory in Patients with Advanced Leukemia T Cells with Chimeric Antigen Receptors Have Potent Antitumor EffectsEditor's Summarythe potential for CAR-modified T cells to bring cancer therapy up to speed.treatment had complete remission of their leukemia. Although this is early in the clinical study, these results highlight scale with a second exposure to CLL cells. Indeed, two of the three CLL patients who underwent the CAR T cell CAR T cells persisted with a memory phenotype, which would allow them to respond more quickly and on a larger these CAR T cells expanded >1000-fold, persisted for more than 6 months, and eradicated CLL cells. Some of these allowing for much broader cellular targeting than is obtained with normal T cells. After transfer into three CLL patients,receptor could activate T cells in response to CD19 in the absence of major histocompatibility complex restriction, specific intracellular signaling domain. The resulting chimeric −specific costimulatory domain and a T cell −both a T cell bind in a restricted manner to the CD19 protein (which is found solely on normal B cells and plasma cells) attached to The CAR T cells used in this study expressed an antigen receptor that consists of antibody binding domains that as reflected by decreased numbers of B cells and plasma cells and the development of hypogammaglobulinemia.tumor cells after transfer into patients; they also mediated cancer remission. Innocent bystanders were also targeted, chronic lymphocytic leukemia (CLL) (a B cell cancer). The designer T cells not only expanded, persisted, and attacked modified T cells to express a chimeric antigen receptor (CAR) to yield so-called CAR T cells that specifically target . have genetically et al cells to the tumor and maintaining these cells in patients remains challenging. Now, Kalos harness the power of the immune system to fight cancers such as leukemia; however, targeting functional immune T to healthy tissues, such as infection or cancer, and then try to deter dangerous activity. Researchers have long sought As members of the body's police force, cells of the immune system vigilantly pursue bad actors that harmGo CAR-Ts in the Fast Lane/content/3/95/95ra73.full.html can be found at:and other services, including high-resolution figures,A complete electronic version of this article /content/suppl/2011/08/08/3.95.95ra73.DC1.htmlcan be found in the online version of this article at: Supplementary Material/about/permissions.dtl in whole or in part can be found at:article permission to reproduce this of this article or about obtaining reprints Information about obtaining last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue (print ISSN 1946-6234; online ISSN 1946-6242) is published weekly, except the Science Translational Medicine o n F e b r u a r y 20, 2012s t m .s c i e n c e m a g .o r g D o w n l o a d e d f r o mL E U K E M I AT Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaMichael Kalos,1,2*Bruce L.Levine,1,2*David L.Porter,1,3Sharyn Katz,4Stephan A.Grupp,5,6 Adam Bagg,1,2Carl H.June1,2†Tumor immunotherapy with T lymphocytes,which can recognize and destroy malignant cells,has been limited by the ability to isolate and expand T cells restricted to tumor-associated antigens.Chimeric antigen receptors(CARs) composed of antibody binding domains connected to domains that activate T cells could overcome tolerance by allowing T cells to respond to cell surface antigens;however,to date,lymphocytes engineered to express CARs have demonstrated minimal in vivo expansion and antitumor effects in clinical trials.We report that CAR T cells that target CD19and contain a costimulatory domain from CD137and the T cell receptor z chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia(CLL).The engineered T cells expanded>1000-fold in vivo,trafficked to bone marrow,and continued to express functional CARs at high levels for at least6months.Evidence for on-target toxicity included B cell aplasia as well as decreased numbers of plasma cells and hypogammaglobulinemia.On average,each infused CAR-expressing T cell was calculated to eradicate at least1000CLL cells.Furthermore,a CD19-specific immune re-sponse was demonstrated in the blood and bone marrow,accompanied by complete remission,in two of three patients.Moreover,a portion of these cells persisted as memory CAR+T cells and retained anti-CD19effector functionality,indicating the potential of this major histocompatibility complex–independent approach for the ef-fective treatment of B cell malignancies.INTRODUCTIONUsing gene transfer technologies,T cells can be genetically modified to stably express antibody binding domains on their surface that con-fer novel antigen specificities that are major histocompatibility com-plex(MHC)–independent.Chimeric antigen receptors(CARs)are an application of this approach that combines an antigen recognition domain of a specific antibody with an intracellular domain of the CD3-z chain or Fc g RI protein into a single chimeric protein(1,2). Trials testing CARs are presently under way at a number of academic medical centers(3,4).In most cancers,tumor-specific antigens are not yet well defined,but in B cell malignancies,CD19is an attractive tumor target.Expression of CD19is restricted to normal and malig-nant B cells(5),and CD19is a widely accepted target to safely test CARs.Although CARs can trigger T cell activation in a manner sim-ilar to an endogenous T cell receptor,a major impediment to the clin-ical application of this technology to date has been the limited in vivo expansion of CAR+T cells,rapid disappearance of the cells after in-fusion,and disappointing clinical activity(4,6).CAR-mediated T cell responses may be further enhanced with ad-dition of costimulatory domains.In a preclinical model,we found that inclusion of the CD137(4-1BB)signaling domain significantly increased antitumor activity and in vivo persistence of CARs com-pared to inclusion of the CD3-z chain alone(7,8).To evaluate the safety and feasibility for adoptive transfer of T cells gene-modified to express such CARs,we initiated a pilot clinical trial using autologous T cells expressing an anti-CD19CAR including both CD3-z and the 4-1BB costimulatory domain(CART19cells)to target CD19+malig-nancies.To date,we have treated three patients under this protocol. Some of the findings from one of these patients are described in(9), which reports that this treatment results in tumor regression,CART19 cell persistence,and the unexpected occurrence of delayed tumor lysis syndrome.Here,we show that the CART19cells mediated potent clinical antitumor effects in all three patients treated.On average,each infused CAR T cell and/or their progeny eliminated more than 1000leukemia cells in vivo in patients with advanced chemotherapy-resistant chronic lymphocytic leukemia(CLL).CART19cells underwent robust in vivo T cell expansion,persisted at high levels for at least6 months in blood and bone marrow(BM),continued to express func-tional receptors on cells with a memory phenotype,and maintained anti-CD19effector function in vivo.RESULTSClinical protocolThree patients with advanced,chemotherapy-resistant CLL were enrolled in a pilot clinical trial for CART19cell therapy.Figure1presents a summary of the manufacturing process for the gene-modified T cells (A)and the clinical protocol design(B).All patients were extensively pretreated with various chemotherapy and biologic regimens(Table1). Two of the patients had p53-deficient CLL,a deletion that portends poor response to conventional therapy and rapid progression(10). Each of the patients had a large tumor burden after the preparative1Abramson Cancer Center,University of Pennsylvania,Philadelphia,PA19104,USA.2De-partment of Pathology and Laboratory Medicine,University of Pennsylvania,Philadelphia, PA19104,USA.3Department of Medicine,University of Pennsylvania,Philadelphia,PA 19104,USA.4Department of Radiology,University of Pennsylvania,Philadelphia,PA19104, USA.5Department of Pediatrics,University of Pennsylvania,Philadelphia,PA19104,USA. 6Division of Oncology,Children’s Hospital of Philadelphia,Philadelphia,PA19104,USA.*These authors contributed equally to this work.†To whom correspondence should be addressed.E-mail:cjune@ o n F e b r u a r y 2 0 , 2 0 1 2 s t m . s c i e n c e m a g . o r g D o w n l o a d e d f r o mchemotherapy,including extensive BM infiltration(40to95%)and lymphadenopathy;UPN02also had peripheral lymphocytosis.There was a low abundance of T cells in the apheresis products(2.29to4.46%) (table S1)as well as likely impaired T cell activation,as has been shown previously in CLL patients(11).Additional details of the cell manufac-turing and product characterization for the CART19cell preparation for each patient are shown in table S1.All patients were pretreated1to 4days before CART19cell infusions with lymphodepleting chemo-therapy(Table1).A split-dose cell infusion schedule was used to address potential safety concerns related to the evaluation of a previously untested CAR that incorporated the4-1BB costimulatory signaling domain. In vivo expansion,persistence,and BM trafficking of CART19cellsOur preclinical data in two animal models,including mice bearing xenografts of primary human precursor-B acute lymphoblastic leuke-mia(7,8),indicated that CAR+T cells that express a4-1BB signaling domain expanded after stimulation with anti-CD3/anti-CD28mono-clonal antibody–coated beads(12)and had improved persistence com-pared to CAR+T cells lacking4-1BB.We developed a quantitative polymerase chain reaction(qPCR)assay to enable quantitative tracking of CART19cells in blood and BM.CART19cells expanded and persisted in the blood of all patients for at least6months(Fig.2, A and B).Moreover,CART19cells expanded1000-to10,000-fold in the blood of patients UPN01and03during the first month after infusion,reaching peak frequencies of10to>95%of circulating white blood cells in UPN01and03(Fig.2C).The peak expansion levels coincided with onset of the clinical symptoms after infusion in UPN01 (day15)and UPN03(day23).Furthermore,after an initial decay,which can be modeled with first-order kinetics,the CART19cell numbers stabilized in all three patients from days90to180after infusion (Fig.2B).The CART19cells also trafficked to the BM in all patients, albeit in5-to10-fold fewer numbers than observed in blood(Fig.2D). CART19cells had a log-linear decay in the BM in UPN01and03, with a disappearance half-life of~35days.Induction of specific immune responses in the peripheral blood and BM compartments after CART19infusion Peripheral blood(PB)and BM serum samples from all patients were collected and batch-analyzed to quantitatively determine cytokine levels.A panel of30cytokines,chemokines,and other soluble factors were assessed for potential toxicities and to provide evidence of CART19cell function.The full data set for all of the cytokines measured in each of the three patients through the date of thisapheresisSeed in gas-permeable bags.Transduction w/αCD19-41BBζvectorVector washout.Culture in gas-permeable bagsCulture in WAV EbioreactorHarvest, wash, concentrateCryopreserve final product ininfusible cryomediaCD3/28-positive selection ofT cells with anti-CD3/anti-CD28 mAb-coated magneticbeadsDay 0Day 0-1Day 3Day 5Harvest day(10 ±2)ABManufacture/cryopreservationFig.1.Schematic representation of the gene transfer vector and trans-gene,gene-modified T cell manufacturing,and clinical protocol design.(A)T cell manufacturing.Autologous cells were obtained via leukapher-esis,and T cells were enriched by mononuclear cell elutriation,washed, and expanded by addition of anti-CD3/CD28–coated paramagnetic beads for positive selection and activation of T cells.Residual leukemic cells were depleted.The lentiviral vector was added at the time of cell activation and was washed out on day3after culture initiation.Cells were expanded on a rocking platform device(WAVE Bioreactor System) for8to12days.On the final day of culture,the beads were removed by passage over a magnetic field and the CART19cells were harvested and cryopreserved in infusible medium.mAb,monoclonal antibody.(B)Clin-ical protocol design.Patients were given lymphodepleting chemo-therapy as described,followed by CART19infusion#1by intravenous gravity flow drip over a period of15to20min.The infusion was given using a split-dose approach over3days(10,30,and60%)beginning1to5days after completion of chemotherapy.Endpoint assays were conducted on study week4.At the conclusion of active monitoring, subjects were transferred to a destination protocol for long-term follow-up as per FDA guidance.onFebruary2,212stm.sciencemag.orgmpublication is presented in tables S2to S5.Of the analytes tested, 11had a threefold or more change from baseline,including four cytokines[interleukin-6(IL-6),interferon-g(IFN-g),IL-8,and IL-10], five chemokines[macrophage inflammatory protein–1a(MIP-1a), MIP-1b,monocyte chemotactic peptide–1(MCP-1),CXC chemokine ligand9(CXCL9),and CXCL10],and the soluble receptors IL-1R a and IL-2R a;IFN-g had the largest relative change from baseline (Fig.3).The peak time of cytokine elevation in UPN01and03 correlated temporally with both the previously described clinical symptoms and the peak levels of CART19cells detected in the blood for each patient.Notably,cytokine modulations were transient,and levels reverted to baseline relatively rapidly despite continued func-Table1.Patient demographics and response.CR,complete response;PR,partial response;N/A,not available.Subject UPNAge/sexkaryotypePrevious therapiesCLL tumor burden at baselineTotaldoseof CART19(cells/kg)Response day+30(duration)BM(study day)‡Blood(studyday)‡Nodes/spleen(study day)‡0165/Mnormal Fludarabine×four cycles(2002)Hypercellular70%CLL N/A 6.2×1011to1.0×1012CLL cells(day−37)1.1×109(1.6×107/kg)CR(11+months)Rituximab/fludarabine×four cycles(2005)2.4×1012CLL cells(day−14)Alemtuzumab×12weeks(2006)1.7×1012CLL cells(day−1)Rituximab(two courses,2008to2009)R-CVP×two cycles(2009)Lenalidomide(2009)PCR×two cycles(5/18/2010to6/18/2010)Bendamustine×one cycle(7/31/10to8/1/10)pre-CART190277/M del(17)(p13)*Alemtuzumab×16weeks(6/2007)Hypercellular>95%CLL2.75×1011CLL cells(day−1)1.2×1012to2.0×1012CLL cells(day−24)5.8×108(1.0×107/kg)PR(7months)Alemtuzumab×18weeks(3/2009)3.2×1012CLL cells(day−47)Bendamustine/rituximab:7/1/2010(cycle1)7/28/2010(cycle2)8/26/2010(cycle3)pre-CART190364/M del(17)(p13)†R-Fludarabine×twocycles(2002)Hypercellular40%CLLN/A 3.3×1011to5.5×1011CLL cells(day−10)1.4×107(1.46×105/kg)CR(10+months)R-Fludarabine×four cycles(10/06to1/07)8.8×1011CLL cells(day−1)R-Bendamustine×one cycle(2/09)Bendamustine×three cycles(3/09to5/09)Alemtuzumab×11weeks(12/09to3/10)Pentostatin/cyclophosphamide(9/10/10)pre-CART19*UPN02karyotype[International System for Human Cytogenetic Nomenclature(ISCN)]:45,XY,del(1)(q25),+del(1)(p13),t(2;20)(p13;q11.2),t(3;5)(p13;q35),add(9)(p22),?del(13)(q14q34),-14,del(17) (p13)[cp24].†UPN03karyotype(ISCN):46,XY,del(17)(p12)[18]/44~46,idem,der(17)t(17;21)(p11.2;q11.2)[cp4]/40~45,XY,-17[cp3].‡See the Supplementary Material for methods of tumor burden determination.o n F e b r u a r y 2 0 , 2 0 1 2 s t m . s c i e n c e m a g . o r g D o w n l o a d e d f r o mtional persistence of CART19cells.Only modest changes in cytokine levels were noted in UPN 02,possibly as a result of corticosteroid treatment.We also noted a robust induction of cytokine secretion in the supernatants from BM aspirates of UPN 03(Fig.3D and table S5).Although a pretreatment marrow sample was not available,compared to the late time point (+176),we also observed elevated levels for a number of factors in the +28marrow sample for UPN 01including IL-6,IL-8,IL-2R,and CXCL9;in contrast,compared to the pretreatment marrow sample,no elevation in cytokines was de-tected in the +31day sample for UPN 02(table S5).One of the preclinical rationales for developing CAR +T cells with 4-1BB signaling domains was a projected reduced propensity to trigger IL-2and tumor necrosis factor –a (TNF-a )secretion compared to CAR +T cells with CD28signaling domains (7);indeed,elevated amounts of soluble IL-2and TNF-a were not detected in the serum of the patients.Lower levels of these cytokines may be related to sustained clinical ac-tivity:Previous studies have shown that CAR +T cells are potentially suppressed by regulatory T cells (13),which can be elicited by either CARs that secrete substantial amounts of IL-2or by the provision of exogenous IL-2after infusion.Moreover,the TNF-a is complicit in cy-tokine storm –related effects in patients,which are absent here.Prolonged receptor expression and establishment of a population of memory CART19cells in bloodA central question in CAR-mediated cancer immunotherapy is whether optimized cell manufacturing and costimulation domains will enhance the persistence of genetically modified T cells and permit the establishment of CAR +memory T cells in patients.Previous studies have not demonstrated robust expansion,prolonged persist-ence,or functional expression of CARs on T cells after infusion (14–17).The high persistence of CART19cells that we observed at late time points for UPN 03facilitated a more detailed phenotypic analysis ofpersisting cells.Flow cytometric analysis of samples from both blood and BM 169days after infusion revealed the presence of CAR19-expressing cells in UPN 03as well as an absence of B cells (fig.S1,Aand B).These CAR +cells persisted in allthree patients beyond 4months,as shown by qPCR (Fig.2).The in vivo frequency of CAR +cells by flow cytometry closely matched the values obtained from the PCR assay for the CAR19transgene.CAR expression was also detected on the surface of 5.7and 1.7%of T cells in the blood of patient UPN 01on days 71and286after infusion (fig.S2).We next used polychromatic flow cy-tometry to perform detailed studies and further characterize the expression,phe-notype,and function of CART19cells in UPN 03using an anti-CAR idiotype anti-body (MDA-647)and the gating strategy shown in fig.S3.We observed differencesin the expression of memory and activa-tion markers in both CD4+and CD8+T cells based on CAR19expression.In the CD4+compartment,at day 56,CART19cells were characterized by auniform lack of CCR7,a predominance of CD27+/CD28+/PD-1+cells distributed within both CD57+and CD57−compart-ments,and an essential absence of CD25and CD127expression,the latter two markers defining regulatory CD4+T cells (18)(Fig.4A).In contrast,CAR −cells at this time point were heterogeneous in CCR7,CD27,and PD-1expression;expressed CD127;and also contained a substantialCD25+/CD127−population.By day 169,although CD28expression remained uni-formly positive in all CART19CD4+cells,a fraction of the CART19CD4+cells had acquired a central memory phenotype,withA CB Day (after infusion)110100100010000100000Day (after infusion)T o t a l c e l l s i n c i r c u l a t i o nDay (after infusion)110100100010000D C o p i e s /µg g D N A% W B CDay (after infusion)C o p i e s /µg gD N AWBC and CART 19: Blood CART 19: Marrow 10101010101010Fig.2.Sustained in vivo expansion and persistence in blood and marrow of CART19cells.(A to D )qPCRanalysis was performed on DNA isolated from whole blood (A to C)or bone marrow (BM)(D)samples obtained from UPN 01,UPN 02,and UPN 03to detect and quantify CAR19sequences.The frequency of CART19cells is shown as average transgene copies (A),total calculated CART19cells in circulation (B),or as a fraction of circulating white blood cells (WBCs)(C).(A)Copies CAR19/microgram DNA is calculated as de-scribed in Materials and Methods.(B)The total number of lymphocytes (total normal and CLL cells)versus total CART19+cells in circulation is plotted for all three subjects using the absolute lymphocyte count from complete blood count values and assuming a 5.0-liter volume of peripheral blood.(C)%WBC is calculated as described in Materials and Methods.(D)Bulk qPCR analysis of marrow to quantify CART19sequences.The data from patient UPN 03in (A,C,and D)has been published in (9)and is reprinted here with permission.Each data point represents the average of triplicate measurements on 100to 200ng of genomic DNA,withmaximal percent coefficient of variation (CV)less than 1.56%.Pass/fail parameters for the assay included preestablished ranges for slope and efficiency of amplification,and amplification of a reference sample.The lower limit of quantification for the assay established by the standard curve range was two copies of transgene per microgram of genomic DNA;sample values below that number are considered estimates and presented if at least two of three replicates generated a C t value with percent CV for the values 15%.CART19cells were infused at days 0,1,and 2for UPN 01and 03and at days 0,1,2,and 11for UPN 02. o n F e b r u a r y 20, 2012s t m .s c i e n c e m a g .o r g D o w n l o a d e d f r o mCCR7expression,a higher percentage of CD27−cells,the appearance of a PD-1−subset,and acquisition of CD127expression.At day 169,CAR −cells remained reasonably consistent with their day 56counterparts,with the exception of a reduction in CD27expression and a decrease in the percentage of CD25+/CD127−cells.In the CD8+compartment,at day 56,CART19CD8+cells displayed primarily an effector memory phenotype (CCR7−,CD27−,CD28−),con-sistent with prolonged and robust exposure to antigen (Fig.4B).In con-trast,CAR −CD8+T cells consisted of mixtures of effector and central memory cells,with CCR7expression in a subset of cells,and substantial numbers of cells in the CD27+/CD28−and CD27+/CD28+fractions.Al-though a large percentage of both CART19and CAR −cell populations expressed CD57,a marker associated with memory T cells with high cytolytic potential (19),this molecule was uniformly coexpressed with PD-1in the CART19cells,a possible reflection of the extensive replicative history of these cells.In contrast to the CAR −cell population,the entirety of the CART19CD8+population lacked expression of both CD25and CD127,markers associated with T cell activation and the development of functional memory cells (20).By day 169,although the phenotype of the CAR −cell population remained similar to the day 56cells,the CART19population had evolved to contain a population with features of central memory cells,notably expression of CCR7and higher levels of CD27and CD28,as well as cells that were PD-1−,CD57−,and CD127+.Effector function of CART19cells after 6months in blood In addition to a lack of long-term persistence,a limitation of previous trials with CAR +T cells has been the rapid loss of functional activity of the infused T cells in vivo.The high level of CART19cell persist-ence and surface expression of the CAR19molecule in UPN 03provided the opportunity to directly test anti-CD19–specific effector functions in cells recovered from cryopreserved PB samples.Pe-ripheral blood mononuclear cells (PBMCs)from UPN 03were cultured with target cells that either did or did not express CD19(Fig.4C and fig.S3).Robust CD19-specific effector function of CART19cells was observed by the specific degranulation of CART19cells against CD19+but not CD19−target cells,as assessed by surface CD107a expression.Notably,exposure of the CART19population to CD19+targets induced a rapid internalization of surface CAR19(see fig.S3for constitutive surface expression of CAR19in the same ef-fector cells in standard flow cytometric staining).The presence of costimulatory molecules on target cells was not required for trigger-ing CART19cell degranulation because the NALM-6line,which was used as a target in these studies,does not express CD80or CD86(21).Effector function was evident at day 56after infusion and was re-tained at day 169(Fig.4C).Robust effector function of CAR +and CAR −T cells could also be demonstrated by pharmacologic stimula-tion with phorbol 12-myristate 13-acetate (PMA)and ionomycin.ADay (after infusion)S e r u m c y t o k i n e (f o l d c h a n g e f r o m b a s e l i n e )(f o l d c h a n g e f r o m b a s e l i n e )S e r u m c y t o k i n e (f o l d c h a n g e f r o m b a s e l i n e )BCDay (after infusion)D Day (after infusion)C o n c e n t r a t i o n (p g /m l )αIL-6 IFN-γCXCL10MIP-1βMCP-1CXCL9IL-2R αIL-8 IL-10MIP-1αFig.3.Serum and BM cytokines before and afterCART19cell infusion.(A to C )Longitudinal measure-ments of changes in serum cytokines,chemokines,and receptors in UPN 01(A),UPN 02(B),and UPN 03(C)on the in-dicated day after CART19cell infusion.(D )Serial assessments of the same analytes in the BM from UPN 03.Analytes with agreater than or equal to threefold change are indicated and plotted as relative change from baseline (A to C)or as absolute values (D).In (C)and (D),a subset of the cytokine data (IFN-g ,CXCL10,CXCL9,IL-2R a ,and IL-6)from UPN 03have been pub-lished in (9)and are reprinted here with permission.Absolutevalues for each analyte at each time point were derived from a recombinant protein-based standard curve over a threefold eight-point dilution series,with upper and lower limits of quantification determined by the 80to 120%observed/expected cutoff valuesfor the standard curves.Each sample was evaluated in duplicate with average values calculated and percent CV in most cases less than 10%.To accommodate consolidated data presentation in the context of the wide range for the absolute values,data are presented as fold change over the baseline value for each analyte.In cases where baseline values were not detectable,half of the lowest standard curve value was used as the baseline value.Standard curve ranges for analytes and baseline (day 0)values (listed in parentheses sequentially for UPN 01,02,and 03),all in pg/ml:IL-1R a :35.5to 29,318(689,301,and 287);IL-6:2.7to 4572(7,10.1,and 8.7);IFN-g :11.2to 23,972(2.8,not detected,and 4.2);CXCL10:2.1to 5319(481,115,and 287);MIP-1b :3.3to 7233(99.7,371,and 174);MCP-1:4.8to 3600(403,560,and 828);CXCL9:48.2to 3700(1412,126,and 177);IL-2R a :13.4to 34,210(4319,9477,and 610);IL-8:2.4to 5278(15.3,14.5,and 14.6);IL-10:6.7to 13,874(8.5,5.4,and 0.7);MIP-1a :7.1to 13,778(57.6,57.3,and 48.1).o n F e b r u a r y 20, 2012s t m .s c i e n c e m a g .o r g D o w n l o a d e d f r o mProfound antitumor clinical activity of CART19cellsThere were no significant toxicities observed during the4days after the infusion in any patient other than transient febrile reactions. However,all patients subsequently developed significant clinical and laboratory toxicities between days7and21after the first infusion. With the exception of B cell aplasia,these toxicities were short-term and reversible.Of the three patients treated to date,there are two complete responses and one partial response lasting greater than8months after CART19infusion according to standard criteria(22).Details of past medical history and response to therapy are described in Table1. The clinical course of UPN03has been described in detail(9).In brief,patient UPN02was treated with two cycles of bendamus-tine with rituximab,resulting in stable disease;he received a third dose of bendamustine as lymphodepleting chemotherapy before CART19 cell infusion.After CART19infusion,and coincident with the onset of high fevers,he had rapid clearance of the p53-deficient CLL cells from his PB(Fig.5A)and a partial reduction of adenopathy.He de-veloped fevers to40°C,rigors,and dyspnea requiring a24-hour hos-pitalization on day11after the first infusion and on the day of his second CART19cell boost.Fevers and constitutional symptoms per-sisted,and on day15,he had transient cardiac dysfunction;all symp-toms resolved after corticosteroid therapy was initiated on day18.His BM showed persistent extensive infiltration of CLL1month after therapy despite marked PB cytoreduction.He remained asymptomatic at the time of publication.Patient UPN01developed a febrile syndrome,with rigors and transient hypotension beginning10days after infusion.The fevers persisted for about2weeks and resolved;he has had no further consti-tutional symptoms.He achieved a rapid and complete response(Fig.5, B and C).Between1and6months after infusion,no circulating CLL cells were detected in the blood by deep sequencing(Table2).His BM at1,3,and6months after CART19cell infusions showed sustainedA1.40.67.890.223.58.02939.5CCR7CD28CD127CCR7CD28CD127C0.999.187.97.10.34.65.165.726.72.60.746.551.71.265.814.34.1715.71.81236.949.49.317.644.129CD4Day 169CCR7CD28CD127CCR7CD28CD127CD45RACD27CD25CD45RACD27CD25CD45RACD27CD25CD45RACD2744.017.34.234.4CD57CD5731.932.111.424.648.218.55.128.2CD57CD57PD-1PD-1PD-1PD-150.111.01127.927.841.716.613.874.719.81.73.8CD57CD57CD57CD5735.933.610.220.352.738.94.63.936.09.814.239.974.9230.61.5CD57CD57CD57CD57CD27CD28CD27CD28CD27CD28CD27CD28CD2565.00.60.433.719.959.411.39.231.551.66.610.030.147.910.811.12.459.635.42.639.59.28.842.5CCR7CD28CD127CD57CD57CD5779.516.70.90.36.833.234.925.110.928.041.319.82542.926.16.014.244.524.516.93.7 2.025.468.875.623.70.20.56.040.339.314.316.328.831.922.937.242.318.12.414.338.222.225.36.0 4.530.359.296.6 3.414.67.41464.15.115.760.418.89.411.464.614.60.60.12.596.818.473.03.05.697.10.70.062.111.2 3.111.873.95.58.052.833.77.8 6.454.231.635.559.21.33.927.264.316.779.20.200.898.97.500.891.73.60.10.395.97.60.40.191.90.10.213.885.90.20.312.387.2C00.284.715.100.969.329.80.10.21188.60.20.56.692.74.00.21.194.73.396.6Fig.4.Prolonged surface CAR19expressionand establishment of functional memoryCART19cells in vivo.(A and B)T cell immuno-phenotyping of CD4+(A)and CD8+(B)T cellsubsets.Frozen peripheral blood(PB)samplesfrom UPN03obtained at days56and169afterT cell infusion were subjected to multipara-metric immunophenotyping for expression ofmarkers of T cell memory,activation,and ex-haustion;data are displayed after biexponentialtransformation for objective visualization ofevents.(C)Functional competence of persistingCAR cells.Frozen PB samples from UPN03ob-tained at days56and169after T cell infusion were evaluated directly ex vivo for the ability to recognize CD19-expressing target cells using CD107 degranulation assays.Presented data are for the CD8+gated population.The gating strategies for these figures are presented in fig.S2.onFebruary2,212stm.sciencemag.orgDownloadedfrom。

达格列净、西格列汀及二甲双胍三联疗法治疗2_型糖尿病疗效研究

达格列净、西格列汀及二甲双胍三联疗法治疗2_型糖尿病疗效研究

DOI:10.16658/ki.1672-4062.2023.19.091达格列净、西格列汀及二甲双胍三联疗法治疗2型糖尿病疗效研究姚矿1,谭嘉睿2,王丽朵21.邵阳市中心医院内分泌科,湖南邵阳422000;2.邵阳学院,湖南邵阳422000[摘要]目的研究达格列净、西格列汀及二甲双胍三联疗法治疗2型糖尿病疗效。

方法选取2022年4月—2023年4月邵阳市中心医院收治的100例2型糖尿病患者为研究对象,用随机数表法将其分为对照组和观察组,各50例。

对照组患者接受二甲双胍单药治疗,观察组患者接受达格列净、西格列汀及二甲双胍三联疗法治疗。

比较两组患者治疗前后的空腹血糖(fasting plasma glucose, FPG)、餐后2 h血糖(2-hour postprandial blood glucose, 2 hPG)、糖化血红蛋白(glycated hemoglobin A1c, HbA1c)、收缩压(systolic blood pressure, SBP)、舒张压(diastolic blood pressure, DBP)及体质指数(body mass index, BMI)等变化水平,同时统计两组患者不良反应发生率。

结果治疗后,观察组患者的HbA1c和FPG水平均明显低于对照组,SBP和BMI均明显低于对照组,差异有统计学意义(P<0.05)。

两组患者DBP和2 hPG比较,差异无统计学意义(P>0.05)。

两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。

结论达格列净、西格列汀及二甲双胍三联疗法治疗2型糖尿病疗效显著,能够有效控制患者血糖水平,改善体质指数,且未增加低血糖发生风险,安全性可靠。

[关键词] 达格列净;西格列汀;二甲双胍;三联疗法;2型糖尿病[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062(2023)10(a)-0091-04Study on the Efficacy of Triple Therapy of Dapagliflozin, Sitagliptin and Metformin in the Treatment of Type 2 Diabetes MellitusYAO Kuang1, TAN Jiarui2, WANG Liduo21.Department of Endocrinology, Shaoyang Central Hospital, Shaoyang, Hunan Province, 422000 China;2.Shaoyang College, Shaoyang, Hunan Province, 422000 China[Abstract] Objective To study the efficacy of triple therapy of dapagliflozin, sitagliptin and metformin in the treat⁃ment of type 2 diabetes mellitus.Methods 100 patients with type 2 diabetes mellitus admitted to Shaoyang Central Hospital from April 2022 to April 2023 were selected as the study objects, and were divided into the control group and the observation group by the randomized numerical table method, with 50 patients in each group. Patients in the control group were treated with metformin monotherapy, and patients in the observation group were treated with triple combination therapy of dapagliflozin, sitagliptin and metformin. Fasting plasma glucose (FPG), 2-hour postprandial glucose (2 hPG), HbA1c, systolic blood pressure (SBP), diastolic blood pressure (DBP), and body mass index (BMI) were compared before and after the treatment of the two groups, and the incidence rates of adverse reactions in the pa⁃tients of the two groups were also counted.Results After treatment, the levels of HbA1c and FPG of patients in the ob⁃servation group were significantly lower than those of the control group, and the SBP and BMI were significantly lower than those of the control group, and the difference was statistically significant (P<0.05). The DBP and 2 hPG values between the two groups were compared, and the difference was not statistically significant (P>0.05). There was no sta⁃tistically significant difference in the incidence of adverse reactions between the two groups of patients (P>0.05).Conclusion Dapagliflozin, sitagliptin and metformin triple therapy for the treatment of type 2 diabetes mellitus has sig⁃nificant efficacy, can effectively control the patient's blood glucose level, improve the body mass index and blood pres⁃sure, and not increase the risk of hypoglycemia, whose safety is reliable.[作者简介]姚矿(1991-),男,硕士,主治医师,研究方向为内分泌内科疾病的诊疗。

欧洲药典7.5版

欧洲药典7.5版
EUROPEAN PHARMACOPOEIA 7.5
INDEX
To aid users the index includes a reference to the supplement in which the latest version of a text can be found. For example : Amikacin sulfate...............................................7.5-4579 means the monograph Amikacin sulfate can be found on page 4579 of Supplement 7.5. Note that where no reference to a supplement is made, the text can be found in the principal volume.
English index ........................................................................ 4707
Latin index ................................................................................. 4739
EUROPEAN PHARMACOPபைடு நூலகம்EIA 7.5
Index
Numerics 1. General notices ................................................................... 7.5-4453 2.1.1. Droppers...................

Separation, structure characterization, conformation and immunomodulating effect of a hyperbranched

Separation, structure characterization, conformation and immunomodulating effect of a hyperbranched

Carbohydrate Polymers 87 (2012) 667–675Contents lists available at SciVerse ScienceDirectCarbohydratePolymersj o u r n a l h o m e p a g e :w w w.e l s e v i e r.c o m /l o c a t e /c a r b p olSeparation,structure characterization,conformation and immunomodulating effect of a hyperbranched heteroglycan from Radix AstragaliJun-Yi Yin a ,b ,1,Ben Chung-Lap Chan a ,1,Hua Yu a ,Iris Yuen-Kam Lau a ,Xiao-Qiang Han a ,Sau-Wan Cheng a ,Chun-Kwok Wong a ,d ,Clara Bik-San Lau a ,Ming-Yong Xie b ,∗∗,Kwok-Pui Fung a ,Ping-Chung Leung a ,Quan-Bin Han a ,c ,∗aState Key Laboratory of Phytochemistry and Plant Resources in West China (CUHK),Institute of Chinese Medicine,The Chinese University of Hong Kong,Shatin,NT,Hong Kong,China bState Key Laboratory of Food Science and Technology,Nanchang University,Nanchang 330047,China cSchool of Chinese Medicine,Hong Kong Baptist University,Hong Kong,China dDepartment of Chemical Pathology,The Chinese University of Hong Kong,Prince of Wales Hospital,Shatin,NT,Hong Kong,Chinaa r t i c l ei n f oArticle history:Received 30June 2011Received in revised form 3August 2011Accepted 17August 2011Available online 24 August 2011Keywords:Radix Astragali PolysaccharideStructure character Morphology featureImmunomodulating effecta b s t r a c tA water soluble polysaccharide (RAP)was isolated and purified from Radix Astragali and its structure was elucidated by monosaccharide composition,partial acid hydrolysis and methylation analysis,and further supported by FT-IR,GC–MS and 1H and 13C NMR spectra,SEM and AFM microscopy.Its aver-age molecular weight was 1334kDa.It was composed of Rha,Ara,Glc,Gal and GalA in a molar ratio of 0.03:1.00:0.27:0.36:0.30.The backbone consisted of 1,2,4-linked Rha p ,␣-1,4-linked Glc p ,␣-1,4-linked GalA p 6Me,␤-1,3,6-linked Gal p ,with branched at O -4of the 1,2,4-linked Rha p and O -3or O -4of ␤-1,3,6-linked Gal p .The side chains mainly consisted of ␣-T-Ara f and ␣-1,5-linked Ara f with O -3as branching points,having trace Glc and Gal.The terminal residues were T-linked Ara f ,T-linked Glc p and T-linked Gal p .Morphology analysis showed that RAP took random coil feature.RAP exhibited significant immunomodu-lating effects by stimulating the proliferation of human peripheral blood mononuclear cells and enhancing its interleukin production.© 2011 Elsevier Ltd. All rights reserved.1.IntroductionRadix Astragali (Astragalus )is the dried root of Astragalus membranaceus (Fisch.)Bunge and Astragalus mongholicus Bunge (Fabaceae).It has been used in the treatment of various renal dis-eases in Traditional Chinese Medicine for over 2000years.Modern researches showed that Radix Astragali possesses a variety of activ-ities,including immunomodulating (Bedir,Pugh,Calis,Pasco,&Khan,2000),anti-hyperglycemic (Chan,Lam,Leung,Che,&Fung,2009),anti-inflammation (Choi et al.,2007),anti-oxidation (Yu,Bao,Wei,&An,2005),antiviral activities (Zhu et al.,2009),etc.Besides saponins and isoflavonoids,polysaccharides are believed as the principle active constituents of Radix Astragali (Chu,Qi,Li,Gao,&Li,2010),which could activate the proliferation and cytokine production of mouse B cells and macrophages (Shao et al.,2004),and showed immunomodulating effects on Peyer’s patch∗Corresponding author.Tel.:+852********.∗∗Corresponding author.Tel.:+8679183969009.E-mail addresses:myxie@ (M.-Y.Xie),simonhan@.hk (Q.-B.Han).1Equal contribution.immunocompetent cells (Kiyohara et al.,2010).The crude polysac-charide could stimulate macrophages to express iNOS gene through the activation of NF-␬B/Rel (Lee &Jeon,2005).It could also amelio-rate the digestive and absorptive function and regulate amino acid metabolism to beneficially increase the entry of dietary amino acid into the systemic circulation (Yin et al.,2009).An acid polysaccha-ride from Radix Astragali showed significant reticuloendothelial system-potentiating activity (Shimizu,Tomoda,Kanari,&Gonda,1991).Scientists made efforts in the structure characterization of the polysaccharides isolated from Radix Astragali (Kiyohara et al.,2010;Shao et al.,2004;Wang,Shan,Wang,&Hu,2006)and only sev-eral glucans (Fang &Wagner,1988;Li &Zhang,2009)were well characterized.As for heteroglycans,nothing but monosaccharide composition and molecular weight was reported (Yan et al.,2010;Zhang et al.,2011).Therefore,their structures deserve further study.Herein we report the isolation and purification of a water-soluble hyperbranched heteroglycan (coded RAP)from Radix Astragali.Its structure was characterized by a combination of chem-ical and instrumental analysis of monosaccharide compositions,methylation,partial acid hydrolysis,FT-IR,ESI-MS,GC–MS and0144-8617/$–see front matter © 2011 Elsevier Ltd. All rights reserved.doi:10.1016/j.carbpol.2011.08.045668J.-Y.Yin et al./Carbohydrate Polymers87 (2012) 667–675NMR.Its morphology feature was further analyzed by scanning electron microscopy(SEM)and atomic force microscopy(AFM). RAP exhibited immunomodulating effects on human peripheral blood mononuclear cells.2.Materials and methods2.1.MaterialThe roots of A.membranaceus were purchased from herbal store in Hong Kong and identified by Dr.Chun-Feng Qiao.The voucher specimens are deposited at the Institute of Chinese Medicine,the Chinese University of Hong Kong,with voucher specimen number 2010-3268.Hiload26/60Superdex-200prep grad was purchased from Pharmacia Co.(Uppsala,Sweden).The dextran standards(T-2000,T-270,T-80,T-50,T-25and T-12with molecular masses of2,000,000,270,000,80,000,50,000and12,000respectively) and monosaccharide standards of d-mannose(Man),l-rhamnose (Rha),d-galactose(Gal),d-arabinose(Ara),and d-glucose(Glc) were obtained from Merck Co.(Darmstadt,Germany).Ultra-pure water was produced by a Milli-Q water purification system(Milli-pore,Bedford,MA,USA).Lipopolysaccharide(LPS)was purchased from Sigma(St.Louis,USA).All chemical reagents were of analytical grade.2.2.Extraction and purification of polysaccharideThe air-dried Radix Astragali(100g)was cut into pieces and extracted twice with boiling water(2×1.2L)for1h.The solution wasfiltered and concentrated under reduced pressure.The solu-tion was precipitated with four volumes of absolute ethanol for 12h.The precipitate was resolved again in water and deproteined using Sevag method(Staub,1965)forfive times.Then the solution was dialyzed against distilled water for72h.Finally,the retentate was lyophilized with Virtis Freeze Dryer(The VirTis Company,New York,USA)to yield crude polysaccharide(RACP,1.67g).RACP was dissolved in distilled water(4mg/mL),filtered through a0.45␮m membrane and separated by the Buchi Puri-fier system(BUCHI Labortechnik AG,Switzerland)coupled with a Hiload26/60Superdex-200(2.6cm×60cm)column,eluted with water at aflow rate of2mL/min.Fractions were collected every 3min and checked using phenol-sulfuric acid under UV detection at490nm.Gel permeation chromatography(GPC)was used to test the homogeneity of the purified polysaccharide.Total carbohydrate was determined using the phenol-sulfuric acid colorimetric method(Dubois,Gilles,Hamilton,Rebers,& Smith,1956).Uronic acid contents were determined accord-ing to Blumenkrantz and Asboe-Hansen’s method(Blumenkr& Asboehan,1973).Protein was estimated by photometric assay using bovine serum albumin as the standard(Bradford,1976). Specific rotation was recorded with a Perkin-Elmer241M digital polarimeter.2.3.Homogeneity and molecular weightThe homogeneity and molecular weight of the purified polysac-charide was determined by GPC.It was analyzed on a Waters UPLC system(Waters,Milford,MA)equipped with a Waters Ultrahydrogel TM1000column(7.8mm×300mm),a Waters ELS Detector,controlled with a Binary Solvent Manager system.The ELS Detector conditions were as follows:drift tube temperature (75◦C),nebulizer temperature(48◦C),gain(300◦C),gas pressure (45Psi).Dextran standards with different molecular weight were used to calibrate the column and establish a standard curve.2.4.Monosaccharide composition analysisRAP was hydrolyzed with2M trifluoroacetic acid(TFA)at120◦C for2h in a sealed test tube.The acid was removed under reduced pressure by repeated evaporation with methanol,and then the hydrolysate was converted into alditol acetates(Chen,Xie,Nie,Li,& Wang,2008;Jones&Albersheim,1972).Shimadzu GC/MS-QP2010 equipment(Nishinokyo Kuwabaracho,Kyoto,Japan)was used for the identification and quantification of monosaccharides.2.5.Methylation and GC–MS analysis2.5.1.Reduction of polysaccharideThe reduction of the uronic acid was conducted following a pro-cedure as described in the literature(Taylor&Conrad,1972)with slight modifications.RAP(20mg)was added into water and treated with1-cyclohexyl-3-(2-morpholinoethyl)-carbodimide methyl-p-toluenesulfonate(CMC)forfive times,until the reduction of uronic acid completed.The polysaccharide after reduction(RAP-R)was subjected to monosaccharide composition and methylation analy-sis.2.5.2.Methylation and GC–MS analysisMethylation analysis of polysaccharide(RAP and RAP-R)was conducted according to the reported methods(Ciucanu&Kerek, 1984;Guo,Cui,Wang,&Christopher Young,2008)with some mod-ifications.The dried polysaccharide was dissolved in anhydrous dimethyl sulphoxide.Dry sodium hydroxide(30mg)was added, and the mixture was stirred for3h at room temperature.Methyl iodide was added into the mixture.The reaction was stopped by adding water.The methylated polysaccharides were then extracted with chloroform followed by washing with distilled water for three times.They were acetylated with acetic anhydride to obtain par-tially methylated alditol acetates(PMAA).GC/MS analysis of PMAA was performed on a DB-5ms capillary column(0.25␮m×0.25␮m×30m)using a temperature program-ming of140◦C(3min)to250◦C(40min)at2◦C/min.Helium was used as the carrier gas.The components were identified by a combi-nation of the main fragments in their mass spectra and relative GC retention times,comparing with the literature(Wang,He,&Huang, 2007).2.6.Partial acid hydrolysisRAP(50.5mg)was treated with0.05M TFA(10mL)at100◦C for1h.The product was concentrated by evaporation of TFA with methanol,and then dialyzed against distilled water(5×500mL, molecular weight3500Da cut off).The solution outside of the dial-ysis bag(RAP-P-L)was collected for monosaccharide analysis and ESI-MS.The solution in the dialysis bag(RAP-P-H)was concen-trated and lyophilized.RAP-P-H’s homogeneity was confirmed by GPC.It was further applied to monosaccharide compositions and methylation analysis.2.7.FT-IR analysisInfrared spectra were recorded with a Thermo Nicolet5700 infrared spectrometer(Madison,WI,USA),using KBr disks method.2.8.NMR spectroscopyRAP was treated with deuterium by lyophilizing with D2O for three times.The deuterium-exchanged RAP(25mg)was put in a5-mm NMR tube and dissolved in0.5mL of99.9%D2O.NMR-spectra were recorded with a Brucker AM-600NMR(Karlsrhue,Germany).J.-Y.Yin et al./Carbohydrate Polymers87 (2012) 667–6756692.9.Molecular morphology analysisPolysaccharide powder was placed on the sample stage,and coated with a thin layer of gold in a MODEL IB-3ion coater(Eiko Corp.,Mito City,Japan).Then it was examined in a QUANTA200F scanning electron microscope(FEI Company,Holland).The sample was viewed at an accelerating voltage of30kV.The atomic force microscopy in this study was manufactured by Shanghai AJ Nano-Science Development Limited(Shanghai,China) and operated in the tapping mode.RAP was diluted to thefinal concentration of5␮g/mL in distilled water.5␮L of solutions was dropped onto freshly cleaved mica and allowed to stand in air before imaging.The quoted spring constant was between5.5and 25N m−1.2.10.Immunomodulatory activities of RAP on human peripheral blood mononuclear cells(PBMC)Immunomodulatory activities of RAP were determined by the capacity of the compounds to influence the cytokine production by human PBMC.PBMCs were obtained from the buffy coat collected from Hong Kong Red Cross by density gradient separation.Buffy coat was diluted1:1with phosphate buffer saline(PBS)and this was overlaid on Ficoll Paque Plus(Amersham Biosciences).Cells were washed with PRMI and plated in96-well plates at105cells/well. Serial dilutions of RAP from10to10,000ng/mL were added to the wells.The plates were maintained in a37◦C incubator for24h. The immunomodulatory effects on PBMC of RAP were compared with a well known mitogen lipopolysaccharide(LPS)from Gram negative bacteria.The cell free supernatants were then assayed for GM-CSF(granulocyte-macrophage colony-stimulating factor), IFN(interferon)-␥,IL(interleukin)-1␤,IL-2,IL-4,IL-10IL-12and TNF(tumor necrosis factor)-␣production by commercially avail-able human cytokine ELISA kits(BD OptEIA,USA)according to the manufacturer instruction with detection limits ranged from3.1to 7.8pg/mL.3.Results and discussion3.1.Isolation and purification of RAPRAP was purified from the crude polysaccharide RACP through a Hiload26/60Superdex-200column.It presented a single and symmetrical peak in GPC(gel-permeation chromatography)exam-ination on an Ultrahydrogel TM1000column(Fig.1).The average molecular weight was1334kDa with reference to Dextran T-series standard samples of known molecular weight.The total sugar con-tent was determined to be76.5%using the phenol-sulfuric acid method.It had a high specific rotation of[␣]D20+125.8(0.54,H2O) and weak UV absorption at280nm which was consistent with its low protein content(only0.72%).The uronic acid content was56.7% using colorimetric method.3.2.Monosaccharide compositions analysisAfter complete hydrolysis of RAP by2M TFA,its monosaccha-ride composition was determined using GC–MS.As demonstrated in Table1,RAP contained Rha,Ara,Glc and Gal.Reduction of RAP with CMC-NaBH4gave the carboxyl-reduced derivative RAP-R and further analysis of RAP and RAP-R both indicated the presence of GalA.The molar ratio of Rha,Ara,Glc,Gal and GalA of RAP was 0.03:1.00:0.27:0.36:0.30,in which the ration of GalA was calculated by the increase of Gal content in RAP-R.Table1Monosaccharide composition of RAP,RAP-R(RAP after reduction),RAP-P-H,RAP-P-L,and RAP-P-L-NH.RAP,after partially hydrolysis followed by dialysis,gave two parts:RAP-P-H(the part in the dialysis bag)and RAP-P-L(the part outside of the dialysis bag).RAP-P-L-NH meant direct examination on the monosac-charides in RAP-P-L before complete hydrolysis.The results were obtained ona Shimadzu GC/MS-QP2010series coupled with a DB-5ms capillary column(0.25␮m×0.25␮m×30m).Samples Mw(kDa)Monosaccharide composition(molar,%)Rha Ara Glc GalRAP13340.03(1.8) 1.00(60.2)0.27(16.3)0.36(21.7) RAP-R n.d.0.01(0.6) 1.00(55.6)0.13(7.2)0.66(36.7) RAP-P-H12150.28(5.4) 1.00(19.2) 1.84(35.3) 2.00(38.4) RAP-P-L n.d.n.d. 1.00(89.3)0.10(8.9)0.02(1.8) RAP-P-L-NH n.d.n.d. 1.00(100.0)n.d.n.d.n.d.not determined.3.3.Methylation analysisRAP and RAP-R were methylated and analyzed by GC–MS in order to elucidate the linkages(Table2).Compared with GalA’s content given in monosaccharide composition analysis,the carboxyl-reduced RAP-R showed a significant increase of1,4-linked Gal p,suggesting the GalA in RAP was1,4-linked.Similarly,it could be suggested that RAP was mainly composed of T-linked Ara f,1,5-linked Ara f,1,4-linked Glc p,1,4-linked GalA p,1,3-linked Glc p and 1,3,6-linked Gal p.The terminals consisted of Ara f(20.6%),Glc p (2.0%)and Gal p(5.2%),indicating RAP was significantly branched and the side chains were terminated by the Ara residues.The ratio of T-,1,5-and1,3,5-linked Ara f(50.9:41.7:7.4)sug-gested that the Ara side chains contained a central core of1,5-linked Ara f residues.The high proportion of T-linked Ara f residues sug-gested that some terminal Ara residues existed in the Ara side chains,and others were attached to the highly branched Gal side chains or connected to the back bone directly(Ros,Schols,& Voragen,1996;Sun,Cui,Tang,&Gu,2010).The proportion of terminal,1,4-,1,3-,1,6-,1,2,4-,1,4,6-and 1,3,6-linked Gal p was9.3:8.7:16.1:8.1:5.0:11.1:41.6.The low pro-portion of terminal residues of Gal(9.3%)indicated that a part of the Gal side chains were terminated by the Ara residues.The Rha residues were exclusively1,2,4-linked.Glc residues were mainly terminal,1,4-linked units,with a small amount of1,3,4-linkedTable2GC–MS analysis for methylation of RAP,RAP-R and RAP-P-H on a DB-5ms capillary column(0.25␮m×0.25␮m×30m).PMAA a Molar ratios b Linkages cRAP RAP-R RAP-P-H2,3,5-Me3-Ara13.420.6 4.2T-2,3-Me2-Ara10.919.89.01,5-2-Me-Ara 2.0 4.3–1,3,5-3-Me-Rha 3.9 5.8 3.91,2,4-2,3,4,6-Me4-Glc 4.4 2.0 4.2T-2,3,6-Me3-Glc24.315.330.11,4-2,6-Me2-Glc 1.9 1.7 3.91,3,4-2,3,4,6-Me4-Gal 3.6 5.27.5T-2,3,6-Me3-Gal 3.414.4 3.31,4-2,4,6-Me3-Gal 6.3 2.014.21,3-2,3,4-Me3-Gal 3.2 1.8 6.91,6-3,6-Me2-Gal 1.90.8–1,2,4-2,3-Me2-Gal 4.4 2.1 5.11,4,6-2,4-Me2-Gal16.3 4.17.51,3,6-–,not determined.a The sugar type was confirmed both with the literature and mass spectrum anal-ysis.b Molar ratios were given as percentage of total ion count(TIC).c The pyranosyl or furanosyl forms of glycosyl residues was confirmed with13C NMR.670J.-Y.Yin et al./Carbohydrate Polymers87 (2012) 667–675Fig.1.GPC chromatogram of RAP on an Ultrahydrogel TM1000column(7.8mm×300mm),mobile phase:water,at aflow rate of0.3mL/min,the ELS Detector conditions were:drift tube temperature(75◦C),nebulizer temperature(48◦C),gain(300◦C),gas pressure(45Psi).Fig.2.The IR spectra of RAP(A)and RAP-P-H(B,partially hydrolyzed RAP),recorded in KBr tablet at the absorbance mode from4000to400cm−1(mid infrared region)at a resolution of4cm−1.J.-Y.Yin et al./Carbohydrate Polymers87 (2012) 667–675671Fig.3.The1H NMR(600.1MHz)spectrum of RAP that was measured in a5-mm NMR tube with0.5mL of99.9%D2O.(A)At27◦C;(B)at50◦C.Fig.4.The13C NMR(151.0MHz)spectra of RAP(A)and RAP-P-H(B,partially hydrolyzed RAP)that were measured in a5-mm NMR tube with0.5mL of99.9%D2O.672J.-Y.Yin et al./Carbohydrate Polymers 87 (2012) 667–675Fig.5.SEM images of RAP at 1000×(A)and 3000×(B).The molecular morphology of RAP was first coated with a thin layer of gold,then observed using SEM at an accelerating voltage of 30kV.units.RAP contained two types of intra-chain linkages for galac-tose,a 1,4-linked that is common in type I arabinogalactan,and a 1,3,6-linked in type II arabinogalactan,suggesting that RAP contain different types of Gal branches.3.4.Partial acid analysisPartial degradation of polysaccharide by acid hydrolysis is based on the fact that some glycosidic linkages are tolerable to acid.To determine more structural features,RAP (50.5mg)was partially hydrolyzed with 0.1M TFA to give two parts,RAP-P-H (in the dialysis bag)and RAP-P-L (outside of the dialysis bag).Direct exam-ination on the monosaccharides in RAP-P-L found only Ara,while after complete hydrolysis it gave a small amount of Glc (9.0%)and Gal (2.1%)in addition to Ara (88.8%)(Table 1).It was suggested that RAP probably contained terminal residues of Ara in the branch areas.There was no GalA found in RAP-P-L in HPLC examination (Honda et al.,1989),which confirmed that GalA was located intheFig.6.AFM image of RAP.RAP was dissolved in distilled water at the concentration of 5␮g/mL.5␮L of solution was dropped onto freshly cleaved mica and allowed to stand in air before imaging.backbone of RAP.These results suggested that GalA and Rha existed in the backbone and the neutral sugars were located in the side chains.ESI-MS of RAP-P-L presented sodium cationized pseu-domolecular ions at m /z 1159.9[Ara 6(Glc/Gal)2+Na]+,997.3[Ara 6(Glc/Gal)+Na]+,702.0[Ara 5+Na]+,569.1[Ara 4+Na]+,407.1[Ara 3+Na]+and 305.1[Ara 2+Na]+.RAP-P-L seemed a mixture of monosaccharide (terminal Ara residues)and oligosaccharide (containing [Ara-Ara]linkages).The degraded polysaccharide RAP-P-H (30mg)was mainly com-posed of Gal and Glc,with small amounts of Rha and Ara (Table 1).Its average molecular weight was 1215kDa.The methylation analy-sis (Table 2)showed that the removal of most Ara f residues resulted in an increase of the ratio of 1,6-linked Gal p and significant increase for 1,3-linked Gal p .Therefore it could be deduced that Ara residues were attached to 1,6-linked and mainly 1,3-linked Gal residues.RAP-P-H gave no 1,3,5-linked Ara f ,suggesting that 1,3,5-linked Ara f should be in the branch.A great amount of 1,4-linked Glc p residues still detected in RAP-P-H indicated that 1,4-linked Glc p residues were located in the backbone of RAP.3.5.FT-IR spectra analysisThe IR spectrum of RAP (Fig.2A)showed a strong band at 3404cm −1which was attributed to the hydroxyl stretching vibra-tion of the polysaccharide.The band at 2935cm −1was due to C–H stretching vibration.Bands at 1743and 1618cm −1indicated the ester carbonyl (COOR)groups and carboxylated ion groups (COO −)(Gnanasambandam &Proctor,2000).The FT-IR spectrum of RAP showed a strong absorbance at 1021,1100and 1142cm −1attributed to the stretching vibrations of ␣-pyranose ring of the glucosyl residue.Moreover,the characteristic absorptions at 830and 916cm −1indicated that both ␣-and ␤-configurations existed.These observations confirmed that the RAP was a polysaccharide containing uronic acid.The IR spectrum of RAP-P-H (Fig.2B)showed the same charac-teristic absorption with RAP which indicated RAP-P-H retained the backbone of RAP.3.6.NMR analysisSignals in the 1H and 13C NMR spectra of RAP were assigned as much as possible,according to monosaccharide compositions analysis,methylation results and literature values (Bock,Pedersen,&Pedersen,1984;Chandra,Ghosh,Ojha,&Islam,2009;Polle,J.-Y.Yin et al./Carbohydrate Polymers87 (2012) 667–675673Fig.7.Cytokines production(GM-CSF,IFN-␥,IL-1␤,IL-2,IL-4,IL-10IL-12and TNF-␣)of human blood mononuclear cells(PBMC)with the addition of RAP or LPS from2to 10,000ng/mL.Each bar represents the mean±SEM of duplicates(n=7).Ovodova,Shashkov,&Ovodov,2002;Sun et al.,2010;Xu,Dong, Qiu,Cong,&Ding,2010).The1H NMR spectrum(Fig.3A)showed signals in the anomeric region.Due to the existence of H2O in the sample or HDO from D2O,there was large signal atı4.815ppm which disturbed the analysis of RAP.Therefore,another1H NMR spectrum was obtained at50◦C(Fig.3B).From methylation analysis,1,4-linked Glc p was the main resides in RAP.So the signal atı5.096ppm was assigned to␣-1,4-linked Glc p.The signal atı 5.254ppm was assigned to␣-1,5-linked Ara f,and the signal atı5.162ppm was originated from␣-1,3,5-linked Ara f.The signal atı4.968ppm was assigned to␣-1,4-linked GalA p6Me,which meant some of1,4-linked GalA p was present as methyl ester.The signal atı4.922could be assigned to␣-1,4-linked GalA p.The signals atı4.693and4.653ppm were assigned to␤-1,3,6-linked Gal p.The signal atı4.469ppm was assigned to␤-1,3-linked Gal p and corresponded with␤-1,3-linked Gal p anomeric carbon resonance atı104.43ppm in the HSQC.The proton signals nearbyı2.083,2.131and2.186ppm could be assigned from the–CH3of the O-acetyl groups.It suggested that RAP contained kinds of O-acetyl groups at the different positions of the sugar residues or different chemical environments.Signal atı1.260ppm was identified to be H-6from methyl group of the Rha residues.The overlapped signals in the range ofı3.355–4.410ppm were assigned to protons H-2to H-5(or H-6)of the glycosidic ring.The anomeric signals in the13C NMR spectrum of RAP (Fig.4A)were assigned partly according to correlations in the HSQC spectrum.The signal atı108.66ppm correlated to H-1 (ı108.66/5.096ppm)of T-Ara f.The signal atı110.48ppm cou-pled to H-1(ı110.48/5.254ppm)of1,5-linked Ara f.The signal atı108.13ppm corresponded to1,3,5-linked Ara f,which was confirmed by its absence in the13C NMR spectrum of RAP-P-H (Fig.4B).The low-field chemical shifts indicated the Ara residues were in furnanose form and adopted␣-anomeric configuration(Xu et al.,2010).Methylation analysis results showed that1,3-linked674J.-Y.Yin et al./Carbohydrate Polymers87 (2012) 667–675Gal p residues increased significantly after partial acid hydrolysis of pared with the13C NMR of RAP,signal atı104.43ppm became much stronger in RAP-P-H.So the signal atı104.43ppm (ı104.43/4.469ppm from HSQC)was assigned to1,3-linked Gal p. The signal atı101.37ppm was assigned to C-1of1,4-linked GalA p. The signals atı101.60and100.18ppm were assigned to C-1 of1,3,6-linked Gal p and␣-1,4-linked GalA p6Me.And the signal atı100.61ppm was assigned to C-1of1,4-linked Glc p.The sig-nal atı62.36ppm was assigned to C-5of a terminal Ara,while the stronger signal atı61.68ppm was attributed to the C-6of 1,4-linked Glc p.The signal atı18.06ppm could be assigned to the methyl carbon of Rha.The signal atı54.15ppm could be assigned to methyl ester groups of RAP.The presence of methyl esterified GalA p was also supported by the signals atı54.15/3.814ppm in HSQC spectrum (Bushneva,Ovodova,Shashkov,&Ovodov,2002).In the lowfield, typical signals for the C-6carboxyl group of GalA were observed at ı176.33and172.06ppm,which confirmed the presence of free and esterified carboxyl groups of GalA.RAP and RAP-R after hydrolysis were acetylated,and no methylated monosaccharide was detected by GC–MS(Samuelsen et al.,1999).It was confirmed that the1,4-linked GalAp was present as1,4-linked GalAp6Me.3.7.Molecular morphology of RAPIts molecular morphology was further investigated by scanning electron microscopy(SEM)and atomic force microscopy(AFM).The SEM micrograph of RAP was shown in Fig.5.RAP appeared as loose flaky and curly aggregation.The observed irregular microstructure demonstrated that RAP was a type of amorphous solid.The molecular morphology of RAP was further investigated by single molecular AFM.The topographical image was shown in Fig.6. The results showed that there were many spherical lumps within the height of3–70nm while the height of a single polysaccharide chain is generally0.1–1nm,which suggested molecular aggrega-tion happened somehow.There might be a repulsive force between the polysaccharide and the mica causing aggregation(Chen et al., 2009)because both RAP and the mica a type of aluminum sili-cate were negative.The side chains might be another reason for the aggregation(Sletmoen,Maurstad,Sikorski,Paulsen,&Stokke, 2003).3.8.Immunomodulatory activities on human peripheral blood mononuclear cells(PBMC)RAP has been investigated for its in vitro effect on the cytokine profile(GM-CSF,IFN-␥,IL-1␤,IL-2,IL-4,IL-10,IL-12and TNF-␣) of unstimulated human PBMC compared with LPS.No significant productions of cytokines were detected in drug free negative con-trol.When RAP was added to RPMI for24h incubations,potent stimulatory effects on the production of two pro-inflammatory cytokines IL-1␤and TNF-␣from PBMC were observed from200to 10,000ng/mL(Fig.7).These cytokines are important in mediating the immune response against bacterial infections.Dose dependent stimulation of IL-10,IL-12and GM-CSF productions from PBMC were also observed with RAP addition but the stimulatory activ-ities was not weaker than LPS.The source of these5cytokines is mainly from monocytes and these results suggested that RAP is an activator of monocytes and further studies are required to inves-tigate its mechanism of action such as the involvement of toll like receptors.For T cell producing cytokines(IL-2,IL-4and IFN-␥),RAP did not produce any significant effects on PBMC(Fig.7).4.ConclusionA water soluble polysaccharide(RAP),with the average molec-ular weight1334kDa,was isolated from Radix Astragali.It was composed of Rha,Ara,Glc,Gal and GalA in a molar ratio of 0.03:1.00:0.27:0.36:0.30.The structure was characterized by par-tial acid hydrolysis,methylation analysis,FT-IR,GC–MS and1H and13C NMR analysis.The backbone of RAP mainly consisted of 1,2,4-linked Rha p,␣-1,4-linked Glc p,␣-1,4-linked GalA p6Me,␤-1,3,6-linked Gal p.It had branches at O-4of the1,2,4-linked Rha p and O-3or O-6of␤-1,3,6-linked Gal p.The side chains mainly consisted of␣-T-Ara f and␣-1,5-linked Ara f possessing O-3as branching points,with trace Glc and Gal.The terminal residues were T-linked Ara f,T-linked Glc p and T-linked Gal p.Morphol-ogy analysis using SEM and AFM showed that RAP took random coil feature.This hyperbranched heteroglycan exhibited significant immunomodulating effects by stimulating the cytokines produc-tion mainly from monocytes in a dose dependent manner. AcknowledgementThis research is funded by the Innovation and Technology Fund (ITS/311/09and InP/108/10)of the Government of the Hong Kong Special Administrative Region.ReferencesBedir,E.,Pugh,N.,Calis,I.,Pasco,D.S.,&Khan,I.A.(2000).Immunostimulatory effects of cycloartane-type triterpene glycosides from Astragalus species.Biological& Pharmaceutical Bulletin,23(7),834–837.Blumenkr,N.,&Asboehan,G.(1973).New method for quantitative determination of uronic acids.Analytical Biochemistry,54(2),484–489.Bock,K.,Pedersen,C.,&Pedersen,H.(1984).Carbon-13nuclear magnetic resonance data for oligosaccharides.Advances in Carbohydrate Chemistry and Biochemistry, 42,193–225.Bradford,M.M.(1976).A rapid and sensitive method for the quantitation of protein utilizing the principle of protein-dye binding.Analytical Biochemistry,72(1–2), 248–254.Bushneva,O.A.,Ovodova,R.G.,Shashkov,A.S.,&Ovodov,Y.S.(2002).Structural studies on hairy region of pectic polysaccharide from campion Silene vulgaris (Oberna behen).Carbohydrate Polymers,49(4),471–478.Chan,J.Y.W.,Lam,F.C.,Leung,P.C.,Che,C.T.,&Fung,K.P.(2009).Antihyper-glycemic and antioxidative effects of a herbal formulation of Radix Astragali Radix Codonopsis and Cortex Lycii in a mouse model of type2diabetes mellitus.Phytotherapy Research,23(5),658–665.Chandra,K.,Ghosh,K.,Ojha,A.K.,&Islam,S.S.(2009).Chemical analysis of a polysaccharide of unripe(green)tomato(Lycopersicon esculentum).Carbohy-drate Research,344(16),2188–2194.Chen,Y.,Xie,M.Y.,Nie,S.P.,Li,C.,&Wang,Y.X.(2008).Purification,composition analysis and antioxidant activity of a polysaccharide from the fruiting bodies of Ganoderma atrum.Food Chemistry,107(1),231–241.Chen,H.X.,Wang,Z.S.,Qu,Z.S.,Fu,L.L.,Dong,P.,&Zhang,X.(2009).Physicochem-ical characterization and antioxidant activity of a polysaccharide isolated from oolong tea.European Food Research and Technology,229(4),629–635.Choi,S.I.,Heo,T.R.,Min,B.H.,Cui,J.H.,Choi,B.H.,&Park,S.R.(2007).Allevi-ation of osteoarthritis by calycosin-7-O-beta-d-glucopyranoside(CG)isolated from Astragali Radix(AR)in rabbit osteoarthritis(OA)model.Osteoarthritis and Cartilage,15(9),1086–1092.Chu,C.,Qi,L.W.,Li,B.,Gao,W.,&Li,P.(2010).Radix Astragali(Astragalus):Latest advancements and trends in chemistry,analysis,pharmacology and pharma-cokinetics.Current Organic Chemistry,14(16),1792–1807.Ciucanu,I.,&Kerek,F.(1984).A simple and rapid method for the permethylation of carbohydrates.Carbohydrate Research,131(2),209–217.Dubois,M.,Gilles,K.A.,Hamilton,J.K.,Rebers,P.A.,&Smith,F.(1956).Colorimetric method for determination of sugars and related substances.Analytical Chemistry, 28(3),350–356.Fang,J.N.,&Wagner,H.(1988).Chemical structure of a glucan from Astragalus mongholicus.Acta Chimica Sinica,46(11),1101–1104.Gnanasambandam,R.,&Proctor,A.(2000).Determination of pectin degree of ester-ification by diffuse reflectance Fourier transform infrared spectroscopy.Food Chemistry,68(3),327–332.Guo,Q.,Cui,S.W.,Wang,Q.,&Christopher Young,J.(2008).Fractionation and physic-ochemical characterization of psyllium gum.Carbohydrate Polymers,73(1), 35–43.Honda,S.,Akao,E.,Suzuki,S.,Okuda,M.,Kakehi,K.,&Nakamura,J.(1989).High-performance liquid chromatography of reducing carbohydrates as strongly ultraviolet-absorbing and electrochemically sensitive1-phenyl-3-methyl5-pyrazolone derivatives.Analytical Biochemistry,180(2),351–357.。

Carboxamides

Carboxamides

专利名称:Carboxamides 发明人:Angelo Storni 申请号:US06/586493申请日:19840305公开号:US04559349A 公开日:19851217专利内容由知识产权出版社提供摘要:The invention relates especially to pharmaceutical preparations containing N-(piperidinyl-alkyl)-carboxamides of the general formula ##STR1## in which R represents hydroxy, hydroxy etherified by an aliphatic alcohol, or halogen,Ar.sub.1 represents a monocyclic arylene or heteroarylene radical,alk represents an alkylene group that separates the two N atoms by at least two carbon atoms,X represents a free or ketalized carbonyl group, free hydroxymethylene or hydroxymethylene esterified by an organic carboxylic acid, or methylene, and Ar.sub.2 represents a monocyclic aryl or heteroaryl radical,and salts thereof, the use of these compounds of the formula I and salts thereof, novel compounds of the formula I and salts thereof in which R, Ar.sub.1, alk, X andAr.sub.2 have the meanings given, with the proviso that the grouping R--Ar.sub.1 is other than a radical of the formula ##STR2## in which R.sub.1 is selected from the group consisting of lower alkyl, trifluoromethyl, halogen, lower alkoxy, nitro and cyano and at least one of the radicals R.sub.1 represents halogen or lower alkoxy, n represents an integer from 1 to 3, and Z represents nitro, amino, lower alkylamino, arylamino, aryl-lower alkylamino, (thio-)formylamino, (thio-) lower alkanoylamino, (thio-)aroylamino or aryl-(thio-)lower alkanoylamino, if alk and X have the meanings given and Ar.sub.2 represents unsubstituted phenyl, thienyl or pyridyl or substituted phenyl having one, two or three substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy, trifluoromethyl and amino, and to processes for the manufacture thereof.申请人:CIBA GEIGY CORPORATION代理人:Michael W. Glynn更多信息请下载全文后查看。

Enzyme promiscuity

Enzyme promiscuity

The wild-type (WT) lipase has a selectivity factor of only E=1.1, in slight favor of (S)-2.
Representation of directed evolution of enzntioselective enzymes
different structures but with similar
free energy. They realized that if each isomer was capable of binding to a different ligand, then functional diversity could go far beyond sequence diversity.
2. SOURCE : Pseudomonas aeruginosa Bacteria 3. EC : 3.1.1.3
Substrate promiscuity
They previously demonstrated that the method of directed evolution can be applied successfully in the quest to create enantioselective enzymes for use in synthetic organic chemistry.
1. Subtilisin is a serine endopeptidase that evolved independently of chymotrypsin. 2. Formerly EC 3.4.21.64.
Condition promiscuity
Use random mutagenesis and screening to identify amino acid substitutions that recover the catalytic activity lost by the serine protease subtilisin E in polar organic solvents.

dehydrogenase

dehydrogenase

CitrateBufferingAs a weak acid, citrate can be used as a component in buffer solutions, including the commonly used SSC 20X hybridization buffer[1]. This buffer uses sodium citrate and sodium chloride to maintain a neutral 7.0 pH. Other buffers may use a mixture of sodium citrate and citric acid - canonical buffer tables compiled for biochemical studies[2] describe solutions of citrate and acid for buffer pHs of between 3.0 and 6.2.ChelatingCitric acid can act as a mild chelating agent. Because of this ability, citrate, usually in the form of trisodium citrate, may be given as an anticoagulant, because it chelates calcium ions and therefore inhibits coagulation.MetabolismMain article: TCA cycleCitrate is an intermediate in the TCA (Krebs) Cycle. After the pyruvate dehydrogenase complex forms acetyl CoA, from pyruvate and five cofactors (Thiaminepyrophosphate, lipoamide, FAD, NAD+, and CoA), citrate synthase catalyzes the condensation of oxaloacetate with Acetyl CoA to form citrate. Citrate continues in the TCA cycle via aconitase with the eventual regeneration of oxaloacetate, which can combine with another molecule of acetyl CoA and continue cycling.Fatty Acid SynthesisCitrate can also be transported out of the mitochondria and into the cytoplasm, then broken down into acetyl CoA for fatty acid synthesis. Citrate is a positive modulator of this convers ion and allosterically regulates the enzyme acetyl-CoA carboxylase, which is the regulating enzyme in the conversion of Acetyl CoA into malonyl CoA (the commitment step in fatty acid synthesis). In short: Citrate is transported to the cytoplasm, converted to Acetyl CoA which is converted into Malonyl CoA by the Acetyl CoA carboxylase enzyme which is allosterically modulated by citrate.See also TCA cycleRole in GlycolysisHigh concentrations of cytosolic citrate can inhibit phosphofructokinase, catalyst of one of the rate-limiting steps of glycolysis.Pyruvate dehydrogenaseFunctionPyruvate dehydrogenase (E1) performs the first two reactions within the pyruvate dehydrogenase complex (PDC): a decarboxylation of substrate 1 (pyruvate) and areductive acetylation of substrate 2 (lipoic acid). Lipoic acid is covalently boundto dihydrolipoamide acetyltransferase (E2), which is the second catalytic component enzyme of PDC.RegulationPhosphorylation of E1 by pyruvate dehydrogenase kinase (PDK) inactivates E1 and subsequently the entire complex. This is reversed by pyruvate dehydrogenase phosphatase. Pyruvate dehydrogenase is stimulated by insulin, PEP, and AMP, but competitively inhibited by ATP, NADH, and Acetyl-CoA.MechanismThe ylide resonance form of thiamine pyrophosphate (TPP) begins by attacking the electrophilic ketone of pyruvate. The intermediate β-alkoxide then decarboxylates and the resulting enol is deprotonated on the carbon atom to form a stabilized 1,3-dipole involving a positively charged nitrogen atom of the thiamine heterocycle. This 1,3-dipole undergoes a reductive acetylation with lipoamide-E2.Biochemical and structural data for E1 revealed a mechanism of activation of TPP cofactor by forming the conserved hydrogen bond with glutamate residue (Glu59 in human E1) and by imposing a V-conformation that brings the N4’ atom of the aminopyrimidine to intramolecular hydrogen bonding with the thiazolium C2 atom. This unique combination of contacts and conformations of TPP leads to formation of the reactive C2-carbanion, eventually. After the cofactor TPP decarboxylates pyruvate, the acetyl portion becomes a hydroxyethyl derivative covalently attached to TPP.[1]Note: The last two steps of this mechanism are not necessary as they just get back to the third intermediate.Reaction of α-ketoglutarateThe reaction catalyzed by this enzyme in the citric acid cycle is:α-ketoglutarate + NAD+ + CoA→Succinyl CoA + CO2 + NADHThis reaction proceeds in three steps:▪decarboxylation of α-ketoglutarate,▪reduction of NAD+ to NADH,▪and subsequent transfer to CoA, which forms the end product, succinyl CoA.ΔG°' for this reaction is -7.2 kcal mol-1. The energy needed for this oxidation isconserved in the formation of a thioester bond of succinyl CoA.RegulationOxoglutarate dehydrogenase is a key control point in the citric acid cycle. It is inhibited by its products, succinyl CoA and NADH. A high energy charge in the cell will also be inhibitive.Mechanism and Activity of malate dehydrogenaseThe active site of malate dehydrogenase is a hydrophobic cavity within the protein complex that has specific binding sites for the substrate and its coenzyme, NAD+. In its active state, MDH undergoes a conformational change that encloses the substrate to minimize solvent exposure and to position key residues in closer proximity to the substrate[8]. The three residues in particular that comprise a catalytic triad are histidine (His-195) and aspartate(Asp-168), which work together as a proton transfer system, and arginines (Arg-102, Arg-109, Arg-171) which secure the substrate[9]. Kinetic studies show that MDH enzymatic activity is ordered. NAD+/NADH is bound before the substrate[10].Active site of malate dehydrogenaseAllosteric RegulationBecause malate dehydrogenase is closely tied to the citric acid cycle, regulation is highly dependent on TCA products. High malate concentrations stimulate MDH activity and conversely, high oxaloacetate concentrations inhibit the enzyme[11]. Citrate can both allosterically activate and inhibit the enzymatic activity of MDH. It inhibits the oxidation of malate when there are low levels of malate and NAD+. However, in the presence of high levels of malate and NAD+, citrate can stimulate the production of oxaloacetate. It is believed that there is an allosteric regulatory site on the enzyme where citrate can bind to and drive the reaction equilibrium in either direction[12].Catalytic mechanism of Isocitrate dehydrogenase Catalytic mechanismIsocitrate + NADP+ Mg2+(metal ion) --> alpha-ketoglutarate + NADPH + H+ + CO2[3][4][5]Catalytic mechanis m of the breakdow n of isocitrate into oxalosuccinate, then into a final product of alpha-ketuglutarate. The oxalosuccinate inter mediate is hypothetical; it has never been observed in the decarboxylating version of the enzy me.[6]Steps broken downWithin the citric acid cycle, isocitrate, produced from the isomerization of citrate, undergoes both oxidation and decarboxylation. Using the enzyme Isocitrate Dehydrogenase (IDH), isocitrate is held within its active site bysurrounding arginine, tyrosine,asparagine, serine, threonine, and aspartic acid amino acids. The first box shows the overall isocitrate dehydrogenase reaction. The reactants necessary for this enzyme mechanism to work are isocitrate, NAD+/NADP+, and Mn2+ or Mg2+. The products of the reaction are alpha-ketoglutarate, carbon dioxide, and NADH + H+/NADPH +H+.[4] Water molecules are used to help deprotonate the oxygens (O3) of isocitrate.The second box is Step 1, which is the oxidation of the alpha-C (C#2).[3][4] Oxidation is the first step that isocitrate goes through. In this process,[3] the alcohol group off the alpha-carbon (C#2) is deprotonated and the electrons flow to the alpha-C forming a ketone group and removing a hydride off C#2 using NAD+/NADP+ as an electron accepting cofactor. The oxidation of the alpha-C allows for a position where electrons (in the next step) will be coming down from the carboxyl group and pushing the electrons (making the double bonded oxygen) back up on the oxygen or grabbing a nearby proton off a nearby Lysine amino acid.The third box is Step 2, which is the decarboxylation of oxalosuccinate. In this step[3][4], the carboxyl group oxygen is deprotonated by a nearby Tyrosine amino acid and those electrons flow down to carbon 2. Carbon dioxide leaves the beta carbon of isocitrate as a leaving group with the electrons flowing to the ketone oxygen off the alpha-C placing a negative charge on the oxygen of the alpha-C and forming an alpha-beta unsaturated double bond between carbons 2 and 3. The lone pair on the alpha-C oxygen picks up a proton from a nearby Lysine amino acid.The fourth box is Step 3, which is the saturation of the alpha-beta unsaturated double bond between carbons 2 and 3. In this step of the reaction,[3][4] Lysine deprotonates the oxygen off the alpha carbon and the lone pair of electrons on the oxygen of the alpha carbon comes down reforming the ketone double bond and pushing the lone pair (forming the double bond between the alpha and beta carbon) off, picking up a proton from the nearby Tyrosine amino acid.[7] This reaction results in the formation of alpha-ketoglutarate, NADH + H+/NADPH + H+, and CO2.Collecting 27 May 2010。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
otif for the iron active site, which we refer to as a 2-His-1-carboxylate facial triad, that contributes to its mechanistic versatility.
The 2-His-1-carboxylatefacial triad
The primary evidence for the 2-His-I -carboxylate facial triad derives t'n iiii the increasing number of crystal structures now available I i o m this class of enzymes. Five mononuclear nonheme iron(I1) enzymes have now been characterized by X-ray crystallography. From a comparison of the active sites of these enzymes (Fig. 2) [3-91, it is clear that the coordination spheres of the iron centers have some common features, despite the very different reactions they catalyze. All five of the enzymes have as endogenous ligands two histidines and one carboxylate that are arranged in an array encompassing one face of the octahedron (Fig. 2). This facial triad motif leaves three remaining sites for binding additional endogenous protein residues and/or exogenous ligands such as substrate(s) that can be used to tune the properties of the metal center. The 2-His-1-carboxylate facial triad is seen most clearly in the crystal structures of the extradiol-cleaving catechol dioxygenase 2,3-dihydroxybiphenyl 1,2-dioxygenase (BphC) and the pterin-dependent tyrosine hydroxylase (TyrH). The structure of BphC, solved independently by two laboratories, contains a square pyramidal iron active site with His145 occupying the axial position and His209 and Glu260 in the basal plane [3, 41. Two solvent molecules complete the metal-coordination sphere. The three endogenous amino acid residues are strictly conserved in the sequences of 35 different extradiol type dioxygenases which require Fe(I1) as well as that for a Mn-dependent dioxygenase [lo]. In the latter case, site-directed mutagenesis was used to demonstrate that these three amino acids are essential for dioxygenase activity [ 1I]. Crystallographic studies on the enzyme-substrate complex show that the substrate coordinates in a bidentate manner [4], as deduced from extended X-ray ab-
Eric L. HEGG and Lawrence QUE Jr Department of Chemistry and Center for Metals in Biocatalysis, University of Minnesota, Minneapolis, USA
(Received 4 July 1997) - EJB 97 094710
A 2-His-I-carboxylate facial triad is a common feature of the active sites in a number of mononuclear non-heme iron(I1) enzymes. This structural motif was established crystallographically for five different classes of enzymes and inferred from sequence similarity for two other classes. The 2-His-1-carboxylate facial triad anchors the iron in the active site and at the same time maintains three additional cis-oriented sites. These sites can be used to bind other endogenous ligands or exogenous ligands such as substrate giving the metal center great flexibility to use different mechanistic strategies to perform a and/or 02, variety of chemical transformations.
Keywords: 2-His-I -carboxylate facial triad; non-heme; oxygenase; iron ; mononuclear.
Mononuclear non-heme iron(I1) enzymes catalyze a diverse range of important reactions in the metabolism of amino acids, nucleic acids, and fatty acids, the biodegradation of aromatic compounds, and the biosynthesis of antibiotics such as penicillin and cephalosporin (Fig. 1) [ I , 21. This emerging class of enzymes now rivals heme enzymes in the diversity of oxidative transformations catalyzed. While many of the mechanistic strategies employed by these two classes of enzymes are similar, there are some significant differences. Heme enzymes feature an iron porphyrin cofactor that is ligated to an amino acid residue on the polypeptide chain; such a ligand environment leaves only one coordination site available for the binding of exogenous ligands, typically 0, for dioxygen-activating enzymes. As a consequence, NADH is the usual source of the two electrons needed for the reaction and a reductase is required to mediate electron transfer into the heme active site. In contrast, mononuclear nonheme iron enzymes employ a variety of electron sources, often metal-bound substrates or cofactors, to reduce 0, to the peroxide oxidation state. This mechanistic feature requires a more flexible metal-coordination environment to allow for the binding of a number of exogenous ligands. Understanding how the ligand environment around the metal center in mononuclear non-heme iron enzymes affects their chemistry and allows them to perform reactions typically associated with their heme counterparts is an area of intense current interest. Emerging from recent crystallographic studies on mononuclear non-heme enzymes is a comCorrespondence to L. Que Jr, Department of Chemistry and Center for Metals in Biocatalysis, University of Minnesota, Minneapolis, MN 55455, USA Fax: +1 612 624 7029. E-mail: que@ Abbreviations. BphC, 2,3-dhydroxybiphenyl 1,2-dioxygenase; TyrH, tyrosine hydroxylase; IPNS, isopenicillin N synthase; ACCO, l-aminocyclopropane-I-carboxylic acid oxidase; FeSOD, superoxide dismutase; SLO-1, soybean lipoxygenase. Note. This Minireview will be reprinted in EJB Reviews 1997 which will be available in April 1998.
相关文档
最新文档